<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01//EN" "http://www.w3.org/TR/html4/strict.dtd">
<!--
-->
<!-- %html{'xmlns'=>'http://www.w3.org/1999/xhtml', 'xml:lang'=>'en', 'lang'=>'en'} -->
<html>
<head>
<script type="text/javascript">window.NREUM||(NREUM={});NREUM.info={"beacon":"beacon-1.newrelic.com","errorBeacon":"jserror.newrelic.com","licenseKey":"d64d3db899","applicationID":"125361","transactionName":"dAkNQBFbXFUEREkBCVQTDlENQB9dDlUTCANZEkxHC1tH","queueTime":0,"applicationTime":1926,"ttGuid":"","agentToken":null,"agent":"js-agent.newrelic.com/nr-298.min.js","extra":""}</script>
<script type="text/javascript">window.NREUM||(NREUM={}),__nr_require=function a(b,c,d){function e(f){if(!c[f]){var g=c[f]={exports:{}};b[f][0].call(g.exports,function(a){var c=b[f][1][a];return e(c?c:a)},g,g.exports,a,b,c,d)}return c[f].exports}for(var f=0;f<d.length;f++)e(d[f]);return e}({"4O2Y62":[function(a,b){function c(a,b){var c=d[a];return c?c.apply(this,b):(e[a]||(e[a]=[]),void e[a].push(b))}var d={},e={};b.exports=c,c.queues=e,c.handlers=d},{}],handle:[function(a,b){b.exports=a("4O2Y62")},{}],YLUGVp:[function(a,b){function c(){var a=m.info=NREUM.info,b=m.proto="https"===l.split(":")[0]||a.sslForHttp?"https://":"http://";if(a&&a.agent&&a.licenseKey&&a.applicationID){f("mark",["onload",e()]);var c=h.createElement("script");c.src=b+a.agent,h.body.appendChild(c)}}function d(){"complete"===h.readyState&&f("mark",["domContent",e()])}function e(){return(new Date).getTime()}var f=a("handle"),g=window,h=g.document,i="readystatechange",j="addEventListener",k="attachEvent",l=(""+location).split("?")[0],m=b.exports={offset:e(),origin:l};h[j]?(h[j](i,d,!1),g[j]("load",c,!1)):(h[k]("on"+i,d),g[k]("onload",c)),f("mark",["firstbyte",e()])},{handle:"4O2Y62"}],loader:[function(a,b){b.exports=a("YLUGVp")},{}]},{},["YLUGVp"]);</script>
<title>
In re Montgomery, 677 F.3d 1375, 102 U.S.P.Q.2d 1881 (Fed. Cir. 2012), Court Opinion - Bloomberg Law 

</title>
<meta content='NOINDEX, NOFOLLOW' name='ROBOTS'>
<meta content='telephone=no' name='format-detection'>
<meta content='BLAW' name='apple-mobile-web-app-title'>
<meta name="csrf-param" content="authenticity_token"/>
<meta name="csrf-token" content="NiJ+70&#47;qv61N1TFnbttr4ZzRa7IGhB5DMvou0CKGUXA="/>
<script src="/min_assets/framework.js?1389213936" type="text/javascript"></script>

<script src="/javascripts/daterange.js?1380743058" type="text/javascript"></script>
<script src="/javascripts/document/document.js?1382459272" type="text/javascript"></script>
<script src="/javascripts/document/document_viewer.js?1383685414" type="text/javascript"></script>
<script src="/javascripts/document/bciteutils.js?1388683076" type="text/javascript"></script>
<script src="/javascripts/jquery/jquery.query.js?1342203941" type="text/javascript"></script>
<script src="/javascripts/browser/browser.js?1387565892" type="text/javascript"></script>
<script src="/javascripts/document/image_viewer.js?1366129555" type="text/javascript"></script>
<script src="/javascripts/jquery/jquery.selection.js?1375450295" type="text/javascript"></script>
<script src="/javascripts/jquery/jquery.bb-copywithcitation.js?1383771008" type="text/javascript"></script>
<script src="/javascripts/document/copy_with_cite.js?1382560939" type="text/javascript"></script>
<script src="/javascripts/document/notepad.js?1366310522" type="text/javascript"></script>

<link href="/stylesheets/yui2/yui2_combo.css?1288273584" media="print,screen" rel="stylesheet" type="text/css" />
<link href="/stylesheets/document_v2.css?1391022004" media="print,screen" rel="stylesheet" type="text/css" />
<link href="/min_assets/framework.css?1391022047" media="screen,print" rel="stylesheet" type="text/css" />
<!--[if IE]>
<link href="/stylesheets/ie.css?1391022010" media="screen,print" rel="stylesheet" type="text/css" />
<![endif]-->
<link href="/stylesheets/search/search_results.css?1391022036" media="print,screen" rel="stylesheet" type="text/css" />
<link href="/stylesheets/document.css?1391022003" media="print,screen" rel="stylesheet" type="text/css" />
<link href="/stylesheets/document_viewer.css?1391022005" media="print,screen" rel="stylesheet" type="text/css" />
<link href="/stylesheets/search/tree_view.css?1391022037" media="print,screen" rel="stylesheet" type="text/css" />
<link href="/stylesheets/browser/browser_enhanced.css?1391021984" media="print,screen" rel="stylesheet" type="text/css" />
<style type='text/css'>
#content_document, #content_document h1, #content_document h2, #content_document h3, #content_document h4, #content_document h5, #content_document h6 { font-family:Times New Roman, Times, serif; }
				#content_document pre {
				white-space: pre-wrap;
				white-space: -moz-pre-wrap;
				white-space: -pre-wrap;
				white-space: -o-pre-wrap;
				word-wrap: break-word;
				font-family: Bloomberg Fixed 2 Unicode;
			}
			
			#content_document .page_no { 
				font-weight:bold;
				text-decoration:none;
			}
			
			#content_document .highlight { 
				font-weight:bold; 
				background-color:yellow; 
				color:black;
			}
			
			#content_document .bcitehi { 
				font-weight:bold; 
				background-color:violet; 
				color:black;
			}
			
			/*.UNICODE {
			}
			
			#content_document blockquote {
			}
			
			#content_document em {
			}   
			
			#content_document .tableofcontents {
			}
			
			#content_document div.blockgroup {
			}
			
			#content_document p.opinion_text {
			}  */
			
			#content_document, #content_document h1, #content_document h2, #content_document h3, #content_document h4, #content_document h5, #content_document h6, #content_document p, #content_document li, #content_document td, #content_document th, #content_document div {
				font-size: 11pt;
			}
			
			#content_document .main {
				text-align:center; 
				font-weight:bold; 
				color:black;
			}
			
			#content_document .ftnote { 
				font-style:italic;
			}
			
			#content_document .headline {
				font-weight:bold; 
				color:black;
			} 
			
			#content_document p.group{
				padding-top: 0; 
				padding-bottom: 1px; 
				padding-left: 0; 
				padding-right: 0;
				margin-top: 0; 
				margin-bottom: 1px; 
				margin-left: 0; 
				margin-right: 0;
			}
			
			#content_document .big {
				font-size: 13pt;
			}
			
			#content_document .indent {
				text-indent:2.5em;
			}
			
			#content_document .level2 {
				margin-left:2.5em;
				margin-right:2.5em;
			} 
			
			#content_document .level3 {
				margin-left:5em;
				margin-right:5em;
			} 					
			
			#content_document .level4 {
				margin-left:7.5em;
				margin-right:7.5em;
			} 					
			
			#content_document .level5 {
				margin-left:10em;
				margin-right:10em;
			} 					
			
			#content_document .level6 {
				margin-left:12.5em;
			} 					
			
			#content_document a.sup {
				font-size: 6pt; 
				vertical-align: top;
			}
			
			#content_document a.sup1 {
				font-size: 8pt; 
				vertical-align: top;
			}
			
			#content_document em.italic {
				font-style: italic;
			}
			
			#content_document em.bold {
				font-weight: bold;
				font-style: normal;
			}
			
			#content_document em.bold-big {
				font-size: 13pt; 
				font-weight: bold;
			}
			
			#content_document em.underline {
				font-style:normal; 
				text-decoration: underline;
			}
			
			#content_document em.bold-ital {
				font-weight: bold; 
				font-style: italic;
			}
			
			#content_document em.bold-underline {
				font-weight: bold; 
				text-decoration: underline;
			}
			
			#content_document em.ital-underline {
				font-style: italic; 
				text-decoration: underline;
			}
			
			#content_document em.ital-bold-underline { 
				font-style: italic; 
				font-weight: bold; 
				text-decoration: underline;
			}
			
			#content_document em.small-cap {
				font-style:normal; 
				font-variant: small-caps;
			}
			
			#content_document em.strike {
				font-style: normal;
				text-decoration: line-through;
			}
			
			#content_document .small-cap {
				font-style:normal; 
				font-variant: small-caps;
			}
			
			#content_document h1.organization {
				font-weight: bold; 
				text-align:center; 
				font-style: normal;
			} 
			
			#content_document h2.organization {
				font-weight: bold; 
				text-align:left;
				margin-left:2.5em; 
				margin-right:2.5em;
			}
			
			#content_document h3.organization {
				font-weight: bold; 
				text-align:left;
				margin-left:5em; 
				margin-right:5em;
			}
			
			#content_document h4.organization {
				font-weight: bold;
				text-align:left;
				margin-left:7.5em; 
				margin-right:5em;
			}
			
			#content_document h5.organization {
				font-weight: bold; 
				text-align:left;
				margin-left:10em; 
				margin-right:5em;
			}
			
			#content_document h2.citation {
				font-weight: bold; 
				text-align:left;
			}
			
			#content_document div.blcitation {
				font-size: 7pt; 
				text-align:center;
			}
			
			#content_document .italic {
				font-style:italic;
			}	
			
			#content_document ul.dash {
				list-style-type: none;
			}
			
			#content_document ul.bullet {
				list-style-type: disc;
			}
			
			#content_document ul.none {
				list-style-type: none;
			}
			
			#content_document li.off {
				list-style-type: none; 
			}
			
			#content_document .mypre { 
				font-size: 100%;
			}
			
			#content_document .TOC {
				text-align:left;  
				padding:5px;  
				margin:0 auto;  
				color: #000000;  
				font-weight: 500;
			}
			
			#content_document .TOC hr { 
				color:#339999;  
				background-color:#339999;  
				width:100%;  
				clear: both;  
				border: none;
			}
			
			#content_document .bluehr { 
				color:#339999;  
				background-color:#339999;  
				width:100%;  
				clear: both;  
				border: none;
			}
			
			#content_document .headinga { 
				color: #339999;   
				font-size: 20px;
				font-weight: 500;
				text-align: center;
			}
			
			#content_document .tocentry {
				text-indent:-18px;
				padding-left:18px;
				color: #003399;
				font-weight: 700;
			}
			
			#content_document .doctext {  
				margin:0 auto;  
				text-align: left;  
			}				 
			
			#content_document span.PAGE { 
				color: black; 
				font-weight: bold 
			}
			
			#content_document a:link {  	
				color: #003399;  
				font-weight: 700;
			}
			
			#content_document a:visited {  
				color: #660066;   
				font-weight: 700;
			}
			
			#content_document .fn{  
				padding-left: 50 px; 
				font-weight: 550;
			}				
			
			#content_document .fr a:link {  
				color: #003399;  
				font-weight: 600;
			}
			
			#content_document .fr a:visited {  
				color: #660066;  
				font-weight: 600;
			}
			
			#content_document .headinga { 
				color: #339999;   
				font-size: 20px;
				font-weight: 600;
				text-align: center;
			}
			
			#content_document .volume {  
				text-align:center;  
				padding:5px;  
				margin:0 auto;  
				color: #000000;  
				font-weight: 500;
			}				
			
			#content_document h2.blcitation {
				font-size: 7pt; 
				text-align:center; 
				white-space:nowrap;
			}
			
			#content_document cite.blcitation {
				white-space:nowrap;
			}
			
			#content_document table.page_legend { 
					width: 100px; 
					text-align: left; 
					background-color: white; 
					font-family: Bloomberg Proportional Unicode;
					font-size: 12px
			}
			#content_document div.page_text {  padding-left: 50 px; margin:0 0 0 50px;  text-align: center;  width:100px; font-size: 12px}

			#content_document .smalllinks{  text-align: right;  font-size: 10px;  font-weight: 500;}		
			
			#content_document .opinion_headnotes{
				margin-top:6px;
				margin-bottom:6px;
			}
			
			#content_document .headnote_group{
				padding: 10px 10px 2px 10px;
				background-color: #ECECEC;
				margin-top:4px;
				margin-bottom:10px;
			}
			
			#content_document .headnote_group_header{
				font-weight: bold;
				margin-bottom: 8px;
			}
			
			#content_document .opinion_headnote{
				clear:both;
				padding-bottom: 4px;
				margin-bottom:10px;
			}
			
			#content_document .highlighted_headnote{
				background-color: #FFFF22;
			}
			
			#content_document .headnote_link{
				font-weight:bold;
				text-decoration: none;
			}
			
			#content_document .show_hide_headnotes{
			}
			
			#content_document .clearfix:after {
				clear:both;
				content: ".";
				height:0px;
				display:block;
				visibility:hidden;
			}
			
			/* BNA Headnotes */
			
			#content_document .headnotesContainer {
				margin: 12px 0;
				padding: 12px 0;
				border-top: 1px solid #000;
				border-bottom: 1px solid #000;
			}
			
			#content_document .headnotesContainer .headnotesContainerTitle {
				font-size: 16px;
				font-weight: bold;
				text-align: center;
			}
			
			#content_document .headnotesContainer .headnoteTitle {
				padding: 8px 12px;
				background-color: #dedede;
				margin: 24px 0 0 0;
				font-size: 16px;
				font-weight: bold;
				text-transform: uppercase;
			}
			
			#content_document .headnotesContainer .headnote {
				margin-left: 24px;
			}
			
			#content_document .headnotesContainer .headnote .headnoteSlug {
				margin-top: 12px;
				font-size: 16px;
				font-weight: bold;
			}
			
			#content_document .headnotesContainer .headnote .headnoteDescriptor {
				margin-top: 12px;
				font-weight: bold;
			}
			
			#content_document .headnotesContainer .headnote .headnoteToggle .headnoteText {
				margin-bottom: 12px;
			}
		
</style>
<link href="/stylesheets/yui_calendar.css?1391022047" media="print,screen" rel="stylesheet" type="text/css" />
<link href="/stylesheets/docviewer_overrides.css?1391022005" media="print,screen" rel="stylesheet" type="text/css" />

<link href="/stylesheets/print.css?1391022029" media="print" rel="stylesheet" type="text/css" />
<link href='/images/favicon.ico' rel='shortcut icon'>
</head>
<body class='securities  document '>
<div class='container'>
<div id='page_loader'></div>
<div class='printHeader printOnly'>
<img src='/images/print_header.jpg'>
<div class='user'>
<span>
Prepared for: Susan Yeh
</span>
</div>
</div>
<div class='topBarHolder printHide'>
<div class='topBar'>
<ul class='topBarElements'>
<li class='skip'>
<a href="#primary_content" tabindex="1">Skip Navigation</a>
</li>
<li class='logout'>
<a href="/log_out.htm" id="logoutButton" onclick="generateExplicitLogoutEvent();">Logout</a>
</li>
<li id='help'>
<a href="/help" target="_blank">Help</a>

</li>
<li id='user'>
<a href="/settings">Susan Yeh</a>

</li>
<li class='withNotifications' id='client_matter'>
<div class='clientMatterDropDown'>
<div>Client Matter</div>
<div class='skinButton blueAlert' style='display:none'>
<span id='currentClientMatter'>

</span>
</div>
<span class='noneSelected' style=''>
&nbsp;(None Selected)
</span>
<div class='expandable'></div>
</div>
<div class='topNavDropdown' id='sub_client_matter'>
<ul>
<li style='display:none'>
<a class='remove_client_matter_menu_item' href='#' onclick='return true;' title='Remove Current Client Matter'>
Remove Current Client Matter
</a>
</li>
<li>
<a class='enter_client_matter_menu_item' href='#' onclick='return true;' title='Enter Client Matter'>
Enter Client Matter
</a>
</li>
</ul>
</div>

</li>
<li class='withNotifications' id='alerts'>
<a href="/alerts/inbox"><div id='unreadAlertsCount'>
Saved Searches & Alerts
</div>
</a>
</li>
<li class='withNotifications' id='downloads'>
<a href="/download/download_center"><div id='unreadDownloadsCount'>
<div>Downloads</div>
</div>
</a>
</li>
<li id='research_trail'>
<a href="/research_trail"><div>Research Trail</div>
</a>
</li>
<li id='workspaces'>
<a href="/workspaces"><div>Workspaces</div>

</a></li>
</ul>
</div>
</div>

<div class='topMenu textBkDark printHide' id='top_menu'>
<div class='contextHolder'>
<a href='/home'>
<h1 class='logo'></h1>
</a>
<div class='menuRow'>
<ul class='menuItems'>
<li class='' id='nav_menu_button'>
<a class='nav_menu_button ' id='nav_menu_button_HOME' onclick="javascript:navigation_selectMenuItem('HOME');">
Home
</a>
</li>
<li class='' id='nav_menu_button'>
<a class='nav_menu_button active' id='nav_menu_button_search' onclick="javascript:navigation_selectMenuItem('search');">
Search & Browse
</a>
</li>
<li class='' id='nav_menu_button'>
<a class='nav_menu_button ' id='nav_menu_button_practice_areas' onclick="javascript:navigation_selectMenuItem('practice_areas');">
Practice Centers
</a>
</li>
<li class='' id='nav_menu_button'>
<a class='nav_menu_button ' id='nav_menu_button_LITIGATION' onclick="javascript:navigation_selectMenuItem('LITIGATION');">
Litigation & Dockets
</a>
</li>
<li class='' id='nav_menu_button'>
<a class='nav_menu_button ' id='nav_menu_button_transactional' onclick="javascript:navigation_selectMenuItem('transactional');">
Transactional Law
</a>
</li>
<li class='' id='nav_menu_button'>
<a class='nav_menu_button ' id='nav_menu_button_LEG_REG' onclick="javascript:navigation_selectMenuItem('LEG_REG');">
Legislative & Regulatory
</a>
</li>
<li class='legalAnalysis' id='nav_menu_button'>
<a class='nav_menu_button ' id='nav_menu_button_news' onclick="javascript:navigation_selectMenuItem('news');">
Legal Analysis & News
</a>
</li>
<li class='last' id='nav_menu_button'>
<a class='nav_menu_button ' id='nav_menu_button_market' onclick="javascript:navigation_selectMenuItem('market');">
Companies & Markets
</a>
</li>

</ul>
</div>
<form accept-charset="UTF-8" action="/autocomplete/jump" id="search_form" method="post"><div style="margin:0;padding:0;display:inline"><input name="utf8" type="hidden" value="&#x2713;" /><input name="authenticity_token" type="hidden" value="NiJ+70/qv61N1TFnbttr4ZzRa7IGhB5DMvou0CKGUXA=" /></div>
<input id='quicksearch_context' name='context_value' type='hidden' value='PRACTICE'>
<div class='searchBox' id='quick_search'>
<div class='inputContainer'>
<input autocomplete='off' id='quick_search_term' name='term' onkeydown='framework_handleTextInput(event,quick_search_term)' tabindex='2' type='text'>
<div class='searchButton' onmouseup='return framework_activateForm();' tabindex='3'></div>
<a href="/help/BLAWHelpSystem.htm#GO_Using_the_GO_BAR.htm" class="infoBtn" target="_blank" title="Using the &lt;GO&gt; Bar"></a>
<input id='quick_search_post' name='qs_type' type='hidden' value='general'>
<input id='quick_search_type' name='type' type='hidden' value='input_terms'>
<input id='quick_search_value' name='item_value' type='hidden'>
<input id='quick_search_origin' name='search_type' type='hidden' value='LAW'>
</div>
</div>
</form>


</div>
</div>

<div class='main clearfix'>
<div class='menuDrawer'>
<div class='interior'>
<div class='drawer_shade drawerShade clearfix'>
<div class='dropShadow'></div>
<div class='sub_menu subMenu' id='sub_menu_HOME'>
<table>
<tr>
<td class=''>
<ul>
</ul>
</td>
</tr>
</table>
</div>
<div class='sub_menu subMenu' id='sub_menu_search'>
<div class='subTitles'>
<div class='subItem one '>
Search
</div>
<div class='subItem two '>
Specialized Searches
</div>
<div class='subItem one last'>
Browse
</div>
<div class='clearfix'></div>
</div>
<table>
<tr>
<td class=''>
<ul>
<li class='last'>
<a class='clearfix' href='/legal_search'>
<div class='navLinkTitle'>
All Legal Content
</div>
</a>
</li>
</ul>
</td>
<td class='subNavGutter'></td>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/company_search'>
<div class='navLinkTitle'>
Company Screener
</div>
</a>
</li>
<li>
<a class='clearfix' href='/opinion_search'>
<div class='navLinkTitle'>
Court Opinions
</div>
</a>
</li>
<li>
<a class='clearfix' href='/dealmaker_document_search'>
<div class='navLinkTitle'>
DealMaker Documents
</div>
</a>
</li>
<li>
<a class='clearfix' href='/dockets'>
<div class='navLinkTitle'>
Dockets
</div>
</a>
</li>
<li>
<a class='clearfix' href='/dnds_search'>
<div class='navLinkTitle'>
Domain Name Decisions
</div>
</a>
</li>
<li>
<a class='clearfix' href='/edgar_search'>
<div class='navLinkTitle'>
EDGAR
</div>
</a>
</li>
<li>
<a class='clearfix' href='/clthreads/company-search-clc.php' target='_blank'>
<div class='navLinkTitle'>
EDGAR Comment Threads
</div>
</a>
</li>
</ul>
</td>
<td class=''>
<ul>
<li>
<a class='clearfix' href='/leg_search'>
<div class='navLinkTitle'>
Legislative
</div>
</a>
</li>
<li>
<a class='clearfix' href='/news/advanced_search'>
<div class='navLinkTitle'>
News
</div>
</a>
</li>
<li>
<a class='clearfix' href='/patent_search'>
<div class='navLinkTitle'>
Patents
</div>
</a>
</li>
<li>
<a class='clearfix' href='/people_search'>
<div class='navLinkTitle'>
People
</div>
</a>
</li>
<li>
<a class='clearfix' href='/reg_search'>
<div class='navLinkTitle'>
Regulatory
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/no_action_search'>
<div class='navLinkTitle'>
SEC No-Action Letters
</div>
</a>
</li>
</ul>
</td>
<td class='subNavGutter'></td>
<td class=''>
<ul>
<li>
<a class='clearfix' href='/law_reports'>
<div class='navLinkTitle'>
BNA Law Reports
</div>
</a>
</li>
<li>
<a class='clearfix' href='/nav_content_menu/105.456024'>
<div class='navLinkTitle'>
BNA Manuals
</div>
</a>
</li>
<li>
<a class='clearfix' href='/nav_content_menu/105.456026'>
<div class='navLinkTitle'>
BNA Portfolios
</div>
</a>
</li>
<li>
<a class='clearfix' href='/nav_content_menu/105.102923'>
<div class='navLinkTitle'>
Books & Treatises
</div>
</a>
</li>
<li>
<a class='clearfix' href='/nav_content_menu/105.293113'>
<div class='navLinkTitle'>
Federal Law
</div>
</a>
</li>
<li>
<a class='clearfix' href='/map_nav/laws_regs'>
<div class='navLinkTitle'>
State Law
</div>
</a>
</li>
</ul>
</td>
</tr>
</table>
</div>
<div class='sub_menu subMenu' id='sub_menu_practice_areas'>
<table>
<tr>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/antitrust'>
<div class='navLinkTitle'>
Antitrust
</div>
</a>
</li>
<li>
<a class='clearfix' href='/banking_finance'>
<div class='navLinkTitle'>
Banking & Finance
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/bankruptcy'>
<div class='navLinkTitle'>
Bankruptcy
</div>
</a>
</li>
</ul>
</td>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/corporate_ma'>
<div class='navLinkTitle'>
Corporate/M&A
</div>
</a>
</li>
<li>
<a class='clearfix' href='/employee_benefits'>
<div class='navLinkTitle'>
Employee Benefits
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/health'>
<div class='navLinkTitle'>
Health
</div>
</a>
</li>
</ul>
</td>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/ip_law'>
<div class='navLinkTitle'>
Intellectual Property
</div>
</a>
</li>
<li>
<a class='clearfix' href='/labor_employment'>
<div class='navLinkTitle'>
Labor & Employment
</div>
</a>
</li>
</ul>
</td>
<td class=''>
<ul>
<li>
<a class='clearfix' href='/securities'>
<div class='navLinkTitle'>
Securities
</div>
</a>
</li>
<li>
<a class='clearfix' href='/tax'>
<div class='navLinkTitle'>
Tax
</div>
</a>
</li>
</ul>
</td>
</tr>
</table>
</div>
<div class='sub_menu subMenu' id='sub_menu_LITIGATION'>
<div class='subTitles'>
<div class='subItem two '>
Litigation
</div>
<div class='subItem two last'>
Dockets
</div>
<div class='clearfix'></div>
</div>
<table>
<tr>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/opinion_search'>
<div class='navLinkTitle'>
Search Court Opinions
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/nav_menu/X7TO28O'>
<div class='navLinkTitle'>
BNA Outlines & Headnotes
</div>
</a>
</li>
</ul>
</td>
<td class=''>
<ul>
<li>
<a class='clearfix' href='/nav_content_menu/105.103000'>
<div class='navLinkTitle'>
Federal Rules
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/general'>
<div class='navLinkTitle'>
Litigation Resources
</div>
</a>
</li>
</ul>
</td>
<td class='subNavGutter'></td>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/dockets'>
<div class='navLinkTitle'>
Search Dockets
</div>
</a>
</li>
<li>
<a class='clearfix' href='/dockets/breaking'>
<div class='navLinkTitle'>
Breaking Complaints
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/dockets/analytics'>
<div class='navLinkTitle'>
Docket Analytics
</div>
</a>
</li>
</ul>
</td>
<td class=''>
<ul>
<li>
<a class='clearfix' href='/dockets/coverage'>
<div class='navLinkTitle'>
Docket Coverage
</div>
</a>
</li>
<li>
<a class='clearfix' href='/dockets/requests'>
<div class='navLinkTitle'>
Docket Requests
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/dockets/tracking'>
<div class='navLinkTitle'>
Docket Tracking
</div>
</a>
</li>
</ul>
</td>
</tr>
</table>
</div>
<div class='sub_menu subMenu' id='sub_menu_transactional'>
<div class='subTitles'>
<div class='subItem two '>
Search
</div>
<div class='subItem two last'>
Resources
</div>
<div class='clearfix'></div>
</div>
<table>
<tr>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/edgar_search'>
<div class='navLinkTitle'>
EDGAR
</div>
</a>
</li>
<li>
<a class='clearfix' href='/clthreads/company-search-clc.php' target='_blank'>
<div class='navLinkTitle'>
EDGAR Comment Threads
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/example_and_saved_searches'>
<div class='navLinkTitle'>
Example Searches
</div>
</a>
</li>
</ul>
</td>
<td class=''>
<ul>
<li>
<a class='clearfix' href='/dealmaker_document_search'>
<div class='navLinkTitle'>
DealMaker Documents
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/dealmaker_clause_search'>
<div class='navLinkTitle'>
DealMaker Clauses
</div>
</a>
</li>
</ul>
</td>
<td class='subNavGutter'></td>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/deal_maker/current_awareness'>
<div class='navLinkTitle'>
Current Awareness
</div>
</a>
</li>
<li>
<a class='clearfix' href='/nav_menu/X7TS80O'>
<div class='navLinkTitle'>
Drafting Guides & Overviews
</div>
</a>
</li>
</ul>
</td>
<td class=''>
<ul>
<li>
<a class='clearfix' href='/nav_menu/X7TVS0O'>
<div class='navLinkTitle'>
Transactional Legal Treatises
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/deal_maker/resources'>
<div class='navLinkTitle'>
Transactional Resources
</div>
</a>
</li>
</ul>
</td>
</tr>
</table>
</div>
<div class='sub_menu subMenu' id='sub_menu_LEG_REG'>
<div class='subTitles'>
<div class='subItem two '>
Legislative
</div>
<div class='subItem two last'>
Regulatory
</div>
<div class='clearfix'></div>
</div>
<table>
<tr>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/leg_search'>
<div class='navLinkTitle'>
Search Legislative
</div>
</a>
</li>
<li>
<a class='clearfix' href='/leg_search/congressional_bill_search'>
<div class='navLinkTitle'>
Search Congressional Bills
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/nav_browser/105.24221'>
<div class='navLinkTitle'>
U.S. Code
</div>
</a>
</li>
</ul>
</td>
<td class=''>
<ul>
<li>
<a class='clearfix' href='/map_nav/laws_regs'>
<div class='navLinkTitle'>
State Legislative Materials
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/leg_news_analysis'>
<div class='navLinkTitle'>
Legislative Resources
</div>
</a>
</li>
</ul>
</td>
<td class='subNavGutter'></td>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/reg_search'>
<div class='navLinkTitle'>
Search Regulatory
</div>
</a>
</li>
<li>
<a class='clearfix' href='/reg_search/federal_register_search'>
<div class='navLinkTitle'>
Search Federal Register
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/nav_browser/105.24230'>
<div class='navLinkTitle'>
Code of Federal Regulations
</div>
</a>
</li>
</ul>
</td>
<td class=''>
<ul>
<li>
<a class='clearfix' href='/map_nav/laws_regs'>
<div class='navLinkTitle'>
State Regulatory Materials
</div>
</a>
</li>
<li>
<a class='clearfix' href='/reg_updates'>
<div class='navLinkTitle'>
Monitor Regulators
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/reg_news_analysis'>
<div class='navLinkTitle'>
Regulatory Resources
</div>
</a>
</li>
</ul>
</td>
</tr>
</table>
</div>
<div class='sub_menu subMenu' id='sub_menu_news'>
<div class='subTitles'>
<div class='subItem two '>
Legal Analysis
</div>
<div class='subItem two last'>
News
</div>
<div class='clearfix'></div>
</div>
<table>
<tr>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/law_reports'>
<div class='navLinkTitle'>
BNA Law Reports
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/nav_content_menu/105.456024'>
<div class='navLinkTitle'>
BNA Manuals
</div>
</a>
</li>
</ul>
</td>
<td class=''>
<ul>
<li>
<a class='clearfix' href='/nav_content_menu/105.456026'>
<div class='navLinkTitle'>
BNA Portfolios
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/nav_content_menu/105.102923'>
<div class='navLinkTitle'>
Books & Treatises
</div>
</a>
</li>
</ul>
</td>
<td class='subNavGutter'></td>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/news/advanced_search'>
<div class='navLinkTitle'>
Search News
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/news'>
<div class='navLinkTitle'>
Legal News
</div>
</a>
</li>
</ul>
</td>
<td class=''>
<ul>
<li>
<a class='clearfix' href='/news/topic'>
<div class='navLinkTitle'>
News by Topic
</div>
</a>
</li>
<li>
<a class='clearfix' href='/news/top_news'>
<div class='navLinkTitle'>
TOP News
</div>
</a>
</li>
</ul>
</td>
</tr>
</table>
</div>
<div class='sub_menu subMenu' id='sub_menu_market'>
<table>
<tr>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/business_development'>
<div class='navLinkTitle'>
Business Development Center
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/edgar_search'>
<div class='navLinkTitle'>
Search EDGAR
</div>
</a>
</li>
</ul>
</td>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/company'>
<div class='navLinkTitle'>
Company Watchlist
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/company_search'>
<div class='navLinkTitle'>
Company Screener
</div>
</a>
</li>
</ul>
</td>
<td class='backgroundExtend'>
<ul>
<li class='last'>
<a class='clearfix' href='/report_writer'>
<div class='navLinkTitle'>
Company Report Writer
</div>
</a>
</li>
</ul>
</td>
<td class=''>
<ul>
<li class='last'>
<a class='clearfix' href='/market'>
<div class='navLinkTitle'>
Market News
</div>
</a>
</li>
</ul>
</td>
</tr>
</table>
</div>

</div>
</div>
<div class='bottomFlange'></div>
</div>
<div class='breadcrumbContainer printHide'>
<div class='breadHolder'>
<!-- .breadcrumb -->
<div class='breadcrumb' id='breadcrumb_0'>
Search & Browse
</div>

<div class='breadcrumbDivider'>
/
</div>
<!-- .breadcrumb -->
<div class='breadcrumb' id='breadcrumb_1'>
<a href='/conversion/resolve_search/0a7288dab8b2e0e9ee9dc2d8937d7419'>
Court Opinions
</a>
</div>

<div class='breadcrumbDivider'>
/
</div>
<!-- .breadcrumb -->
<div class='breadcrumb' id='breadcrumb_2'>
<a href='/opinion_search/results/0a7288dab8b2e0e9ee9dc2d8937d7419'>
Search Results
</a>
</div>

<div class='breadcrumbDivider'>
/
</div>
</div>
</div>

</div>
<div class='page clearfix'>
<div class='content' id='page_content'>
<div id='statusHolder'></div>
<a name='primary_content'></a>
<div class='document_search_links_container printHide'>
<div class='prev_search_result_container'>
<div class='attachmentPanelBackButton' onclick="document.location = $('.prev_search_result_link a').attr('href')"></div>
<div class='prev_search_result_link'>
<a href="/s/opinion/0a7288dab8b2e0e9ee9dc2d8937d7419/document/X1HN29U003?search32=DPNLUQBDE1FN0Q3IC5PMASPT64TJMSRPDPNMSUBDECUJ2" class="{}" data-doc-id="X1HN29U003">Previous Result: <span>Simpson v. Kohl&#x27;s Dept. Stores, Inc., CI...</span></a>
<div class='clearfix'></div>
</div>
</div>
<div class='next_search_result_container'>
<div class='next_search_result_link'>
<a href="/s/opinion/0a7288dab8b2e0e9ee9dc2d8937d7419/document/X1HN2A0003?search32=DPNLUQBDE1FN0Q3IC5PMASPT64TJMSRPDPNMSUBDECUJ2" class="{}" data-doc-id="X1HN2A0003">Next Result: <span>Clemente v. Clemente (In re Clemente), C...</span></a>
<div class='clearfix'></div>
</div>
<div class='attachmentPanelForwardButton' onclick="document.location = $('.next_search_result_link a').attr('href')"></div>
</div>
<div class='clearfix'></div>
</div>
<div class='clearfix'></div>

<div class='breadCrumbTitleRow clearfix eight grid'>
<div class="icon citation positive" title="Positive"></div>
<div class='title left' title='In re Montgomery, 677 F.3d 1375, 102 U.S.P.Q.2d 1881 (Fed. Cir. 2012), Court Opinion'>
In re Montgomery, 677 F.3d 1375, 102 U.S.P.Q.2d 1881 (Fed. Cir. 2012), Court Opinion
</div>
</div>

<div class='metadata' style='display: none'>
<div class='documentTitle'>In re Montgomery, 677 F.3d 1375, 102 U.S.P.Q.2d 1881 (Fed. Cir. 2012), Court Opinion</div>
<div class='docId'>X1HMT8G003</div>
<div class='docType'>OPINIONS</div>
<div class='case_name'>In re Montgomery</div>
<div class='displayCitation'>102 U.S.P.Q.2d 1881</div>
<div class='displayCitation'>2012 BL 112237</div>
<div class='displayCitation'>677 F.3d 1375</div>
<div class='displayCitation'>bna a0d1v4z7m6</div>
<div class='displayCitation'>bna a0d2n4y6r4</div>
<div class='displayCitation'>wkffecase:26065544</div>
</div>

<div class='search_outline_node_popup' style='display:none'>
<form accept-charset="UTF-8" action="/document/class_outline_search" id="search_document_node_form" method="post"><div style="margin:0;padding:0;display:inline"><input name="utf8" type="hidden" value="&#x2713;" /><input name="authenticity_token" type="hidden" value="NiJ+70/qv61N1TFnbttr4ZzRa7IGhB5DMvou0CKGUXA=" /></div>
<div class='clearfix popupTitle'>
<div class='close' onclick='closePopup()'></div>
<h2>Search</h2>
</div>
<p class='searchOver'>
Search over:
<span class='search_target_node'></span>
<input class="search_source_id" id="source_id" name="source_id" type="hidden" />
<input class="search_node_id" id="search_node_id" name="search_node_id" type="hidden" />
<input class="search_service_code" id="search_service_code" name="search_service_code" type="hidden" />
<input class="search_division" id="search_division" name="search_division" type="hidden" />
<input autocomplete="off" class="search_node_text" id="search_term" name="search_term" type="text" />
</p>
<div class='clearfix'></div>
<div class='popUpActions'>
<button class='bootstrap skinButton popup action right print' onclick='this.form.submit();'>
<span>
Search
</span>
</button>
<button class='bootstrap skinButton popup cancel right' onclick='closePopup();' type='button'>
<span>
Cancel
</span>
</button>
</div>
</form>

</div>
<div id='no_matching_keywords_popup' style='display:none'>
<div class='popupTitle clearfix'>
<div class='close' onclick='closePopup()'></div>
<h2>No Matches Found</h2>
</div>
<p>
Search term(s) not found.
</p>
<div class='popUpActions'>
<button class='bootstrap skinButton popup cancel right' onclick='closePopup();' type='button'>
<span>
Close
</span>
</button>
</div>
</div>
<div id='copyWithCitationPopupContents' style='display:none'>
<div class='popupTitle clearfix'>
<div class='close' onclick='closePopup()'></div>
<h2>Copy with Citation</h2>
</div>
<p>
Copy the text below to paste into your document.
</p>
<div class='clearfix'>
<div class='copyWithCitationScrollBox'>
<div class='copyWithCitationArea left'>
<div class='copyWithCitationText'></div>
<div class='copyWithCitationDocumentTitle'></div>
</div>
<div class='ie9compat left'>
<img alt="" src="/images/transparency.png?1296705112" width="1" />
</div>
</div>
</div>
<div class='copyWithCitationCheckBoxHolder'>
<input checked="checked" class="linkCitation" id="link_citation" name="link_citation" onclick="updateCopyWithCitationLinks()" type="checkbox" value="true" />
Link citations to Bloomberg Law
</div>
<div class='popUpActions'>
<button class='bootstrap skinButton popup action right' onclick='closePopup();' type='button'>
<span>
Close
</span>
</button>
</div>
</div>

<script type='text/javascript'>
  //<![CDATA[
    $('#page_content').addClass("invisible");
  //]]>
</script>
<input id="doc_id" name="doc_id" type="hidden" value="X1HMT8G003" />
<input id="hidden_document_title" name="hidden_document_title" type="hidden" value="In re Montgomery, 677 F.3d 1375, 102 U.S.P.Q.2d 1881 (Fed. Cir. 2012), Court Opinion" />
<input id="hidden_case_name" name="hidden_case_name" type="hidden" value="In re Montgomery" />
<input id="hidden_case_docket" name="hidden_case_docket" type="hidden" />
<div class='toolHolder'>
<form accept-charset="UTF-8" action="" id="downloadPopupLinkForm" method="post"><div style="margin:0;padding:0;display:inline"><input name="utf8" type="hidden" value="&#x2713;" /><input name="authenticity_token" type="hidden" value="NiJ+70/qv61N1TFnbttr4ZzRa7IGhB5DMvou0CKGUXA=" /></div><input id="pde_location_type" name="pde_location_type" type="hidden" value="DOCUMENT" /><input id="full_doc_path" name="full_doc_path" type="hidden" value="/s/opinion/0a7288dab8b2e0e9ee9dc2d8937d7419/document/X1HMT8G003?search32=DPNLUQBDE1FN0Q3IC5PMASPT64TJMSRPDPNMSUBDECUJ2" /><input id="document_type" name="document_type" type="hidden" value="OPINIONS" /><input id="doc_id" name="doc_id" type="hidden" value="X1HMT8G003&amp;search32=DPNLUQBDE1FN0Q3IC5PMASPT64TJMSRPDPNMSUBDECUJ2" /><input id="artifact_id" name="artifact_id" type="hidden" value="X1HMT8G003" /><input id="title" name="title" type="hidden" value="In re Montgomery, 677 F.3d 1375, 102 U.S.P.Q.2d 1881 (Fed. Cir. 2012), Court Opinion" /><input id="search32" name="search32" type="hidden" value="DPNLUQBDE1FN0Q3IC5PMASPT64TJMSRPDPNMSUBDECUJ2" /><input id="citation_analysis" name="citation_analysis" type="hidden" value="POSITIVE" /><input id="context_resource_id" name="context_resource_id" type="hidden" value="0a7288dab8b2e0e9ee9dc2d8937d7419" /><input id="has_sidebar_info" name="has_sidebar_info" type="hidden" value="true" /><input id="tab_types_" name="tab_types[]" type="hidden" value="TAB_OPINION" /><input id="has_notepad" name="has_notepad" type="hidden" value="true" /><input id="notepad_id" name="notepad_id" type="hidden" value="X1HMT8G003" /><input id="has_headnotes" name="has_headnotes" type="hidden" value="true" /><input id="preselect_option" name="preselect_option" type="hidden" value="DOCUMENT" /></form>

<ul class='tools printHide'>
<li>
<a href="#" onclick="javascript:quickPrintLink(); return false;">Quick Print</a>

</li>
<li>
<a href="#" onclick="javascript:createFormPopupFromForm('download','downloadPopupLinkForm'); return false;">Print/Download</a>
</li>
<li>
<a href="#" onclick="javascript:createFormPopupFromForm('email','downloadPopupLinkForm'); return false;">Email</a>
</li>
<li>
<a href="#" onclick="javascript:addPopupForm('add_to_workspace','?resource_path=%2Fs%2Fopinion%2F%30a%37%32%38%38dab%38b%32e%30e%39ee%39dc%32d%38%39%33%37d%37%34%31%39%2Fdocument%2FX%31HMT%38G%30%30%33%3Fsearch%33%32%3DDPNLUQBDE%31FN%30Q%33IC%35PMASPT%36%34TJMSRPDPNMSUBDECUJ%32&amp;document_type=OPINIONS', null); return false;">+ Workspace</a>
</li>
<li>
<a onclick='javascript:PDETray_default.addSelection();'>
+ Queue
</a>
</li>
<li class='last'></li>
</ul>
</div>

<div class='bootstrap printHide tabs'>
<a class='borderTab activeTab' id='tab_DOCUMENT'>
Document
</a>

<a href="/s/opinion/0a7288dab8b2e0e9ee9dc2d8937d7419/bcite/X1HMT8G003/history" class="borderTab inactiveTab" id="tab_HISTORY" onclick="docTabSpinner()">Direct History</a>

<a href="/s/opinion/0a7288dab8b2e0e9ee9dc2d8937d7419/bcite/X1HMT8G003/analysis" class="borderTab inactiveTab" id="tab_ANALYSIS" onclick="docTabSpinner()">Case Analysis</a>

<a href="/s/opinion/0a7288dab8b2e0e9ee9dc2d8937d7419/bcite/X1HMT8G003/toa" class="borderTab inactiveTab" id="tab_TOA" onclick="docTabSpinner()">Table of Authorities</a>

<a href="/s/opinion/0a7288dab8b2e0e9ee9dc2d8937d7419/related_content/X1HMT8G003?search32=DPNLUQBDE1FN0Q3IC5PMASPT64TJMSRPDPNMSUBDECUJ2" class="borderTab inactiveTab" id="tab_CITING_DOCS" onclick="docTabSpinner()">Citing Documents</a>

<div class='showHide printHide'>
<div class='showHideSidebarArrow'>
<a class='bliderText' id='bliderLink'>
<span id='bliderText'>
Hide General Info & Notepad
</span>
<span id='notepadCountLabel'></span>
</a>
</div>
</div>

</div>

<!-- document -->
<script type='text/javascript'>
  //<![CDATA[
    var fluid_layout=false;
  //]]>
</script>

<!-- %table.markupContainment -->
<!-- %tbody -->
<!-- %tr -->
<!-- %td#markup_holder{:valign=>"top", :align=>"left"} -->
<div class='docHolder legal hasSearchTerms ' id='doc_holder'>
<div class='documentContent ' id='content_document'>


<script type="text/javascript">
					function Blaw__Citator()
					{
						window.location="bloomberg:bcite_url_prefix=/rest/documents/1708231491587";
					}
				</script><script type="text/javascript">
      var BLAW_TOTAL_KEYWORD = 0;
      var BLAW_CURRENT_KEYWORD = -1;
      var BLAW_LAST_COLOR = "yellow";
      var BLAW_ANCHOR_NAME = "blawkeyword";
      var BLAW_BASE_URL = document.location.href;

      function Blaw__changeCurElem(lastAnchor, newAnchor)
      {
        var baseUrl = Blaw__getBaseURL(document.location.href);
        document.location.href = baseUrl + "#" + newAnchor;
        var elem = document.getElementById(lastAnchor)[0];
        if (elem) {
          elem.style.backgroundColor = BLAW_LAST_COLOR;
        }
        elem = document.getElementById(newAnchor)[0];
        if (elem) {
          BLAW_LAST_COLOR = elem.style.backgroundColor;
          elem.style.backgroundColor = "orange";
        }
      }

      function Blaw__findNextKeyWord()
      {
        var looped = false;
        var lastAnchor = BLAW_ANCHOR_NAME + BLAW_CURRENT_KEYWORD;
        if (++BLAW_CURRENT_KEYWORD >= BLAW_TOTAL_KEYWORD) {
          BLAW_CURRENT_KEYWORD = 0;
        }

        // if index does not exist on page continue to inc until one does
        while(document.getElementById(BLAW_ANCHOR_NAME + BLAW_CURRENT_KEYWORD).length == 0 && BLAW_CURRENT_KEYWORD < BLAW_TOTAL_KEYWORD) {
            ++BLAW_CURRENT_KEYWORD;
            // wrap around search, once only
            if (BLAW_CURRENT_KEYWORD >= BLAW_TOTAL_KEYWORD && !looped) {
              BLAW_CURRENT_KEYWORD = 0;
              looped = true;
            }
        }
        var newAnchor = BLAW_ANCHOR_NAME + BLAW_CURRENT_KEYWORD;
        Blaw__changeCurElem(lastAnchor, newAnchor);
      }

      function Blaw__findPrevKeyWord()
      {
        var looped = false;
        var lastAnchor = BLAW_ANCHOR_NAME + BLAW_CURRENT_KEYWORD;
        if (--BLAW_CURRENT_KEYWORD < 0) {
          BLAW_CURRENT_KEYWORD = BLAW_TOTAL_KEYWORD - 1;
          looped = true;
        }

        // if index does not exist on page continue to decr until one does
        while(document.getElementById(BLAW_ANCHOR_NAME + BLAW_CURRENT_KEYWORD).length == 0 && BLAW_CURRENT_KEYWORD >= 0) {
          --BLAW_CURRENT_KEYWORD;
          // wrap around search, once only
          if (BLAW_CURRENT_KEYWORD < 0 && !looped) {
            BLAW_CURRENT_KEYWORD = BLAW_TOTAL_KEYWORD - 1;
            looped = true;
          }
        }
        var newAnchor = BLAW_ANCHOR_NAME + BLAW_CURRENT_KEYWORD;
        Blaw__changeCurElem(lastAnchor, newAnchor);
      }

      function Blaw__findNextFrom(indx)
      {
        var lastAnchor = BLAW_ANCHOR_NAME + BLAW_CURRENT_KEYWORD;
        BLAW_CURRENT_KEYWORD = indx;
        ++BLAW_CURRENT_KEYWORD;
        if (BLAW_CURRENT_KEYWORD >= BLAW_TOTAL_KEYWORD) {
          BLAW_CURRENT_KEYWORD = 0;
        }
        var newAnchor = BLAW_ANCHOR_NAME + BLAW_CURRENT_KEYWORD;
        Blaw__changeCurElem(lastAnchor, newAnchor);
      }

      function Blaw__getBaseURL(url)
      {
        var reg = new RegExp("(.+)#.+$");
        var ar = reg.exec(url);
        if (ar != null) {
          return ar[1];
        } else {
          return url;
        }
      }


    </script><div xmlns:fo="http://www.w3.org/1999/XSL/Format" class="metadata" style="display: none">
<div class="pagination_series_list">PrimaryFederalReporter,ReporterOfDecisions,Bloomberg,</div>
<div class="citation-group">
<div class="cite" data-cite-type="PrimaryFederalReporter">677 F.3d 1375</div>
<div class="cite" data-cite-type="ReporterOfDecisions">102 U.S.P.Q.2d 1881</div>
<div class="cite" data-cite-type="DocketNumber">2011-1376</div>
<div class="cite" data-cite-type="Bloomberg">2012 BL 112237</div>
</div>
</div>
<div align="left" class="tableofcontents">
<br CLEAR="right"><div class="page_text" style="float:right">
<b>Pagination</b><table class="page_legend" cellspacing="0">
<tr>
<td width="25%" align="left" valign="top">*</td>
<td width="50%" align="left" valign="top">F.3d </td>
</tr>
<tr>
<td width="25%" align="left" valign="top">**</td>
<td width="50%" align="left" valign="top">U.S.P.Q.2d </td>
</tr>
<tr>
<td width="25%" align="left" valign="top">***</td>
<td width="50%" align="left" valign="top">BL</td>
</tr>
</table>
</div>
<br>
</div>
<table><tbody><tr><td>&nbsp;</td></tr></tbody></table>
<p><center>
United States Court of Appeals, Federal Circuit.
</center></p>
<hr align="center" width="65%">
<p><center>
In re Hugh Edward MONTGOMERY, John Francis Martin, and Jorge Daniel
Erusalimsky.
</center></p>
<hr align="center" width="65%">
<p><center>
No. 2011-1376.
</center></p>
<p><center>
May 8, 2012.
<span CLASS="page_no" data-cite="102 uspq 2d 1882" data-cite-type="ReporterOfDecisions" data-cite-pageno="1882" data-primary-citation="102 U.S.P.Q.2d 1881">[**1882]</span> </center></p>
<div class="headnotesToggle clearfix"><button id="toggle_headnotes_button" class="bootstrap skinButton sourceButton wide right hideSource" data-target="#headnotes_container"><span>Hide Headnotes</span></button></div>
<div class="headnotesContainer" id="headnotes_container">
<div class="headnotesContainerTitle">BNA Headnotes</div>
<div class="headnoteTitle"><a href="http://www.bloomberglaw.com/document/1475619602000128">U.S. Patents Quarterly</a></div>
<div xmlns:fo="http://www.w3.org/1999/XSL/Format" class="headnote">
<div class="headnoteSlug">PATENTS</div>
<div class="headnoteDescriptor">
<a name="headnote_pq2-dec_915532" href="#headnote_ref_pq2-dec_915532">[1]</a> <span>Patentability/Validity &mdash; Anticipation &mdash; Identity of elements </span> <a href="http://www.bloomberglaw.com/document/1708231491587/class_outline_search?source_id=105.455998&amp;search_service_code=pq2co-ref&amp;search_node_id=115.0704" rel="ref" data-source-id="105.455998" data-service-code="pq2co-ref" data-node-id="115.0704">&#9658;115.0704</a> <span class="headnoteToggle">[<a href="#headnote_content_pq2coref_1" data-source-id="105.455998" class="toggle">Show Topic Path</a>]</span>
</div>
<div id="headnote_content_pq2coref_1" class="headnoteContent"></div>
<div class="headnote_text">
Method claims in patent application directed to inhibitors of renin-angiotensin system, which require, in pertinent part, that method be used &ldquo;for the treatment or prevention of stroke or its recurrence,&rdquo; are inherently anticipated by prior art reference describing design for study of RAS inhibitor ramipril in prevention of cardiovascular events such as myocardial infarction or stroke, even if it is assumed that broadest reasonable interpretation of claims includes efficacy requirement, since it is undisputed that ramipril is effective at preventing or treating stroke, and since administering ramipril to stroke-prone patients thus inevitably treats or prevents stroke.</div>
</div>
<div xmlns:fo="http://www.w3.org/1999/XSL/Format" class="headnote">
<div class="headnoteDescriptor">
<a name="headnote_pq2-dec_915533" href="#headnote_ref_pq2-dec_915533">[2]</a> <span>Patentability/Validity &mdash; Anticipation &mdash; Identity of elements </span> <a href="http://www.bloomberglaw.com/document/1708231491587/class_outline_search?source_id=105.455998&amp;search_service_code=pq2co-ref&amp;search_node_id=115.0704" rel="ref" data-source-id="105.455998" data-service-code="pq2co-ref" data-node-id="115.0704">&#9658;115.0704</a> <span class="headnoteToggle">[<a href="#headnote_content_pq2coref_2" data-source-id="105.455998" class="toggle">Show Topic Path</a>]</span>
</div>
<div id="headnote_content_pq2coref_2" class="headnoteContent"></div>
<div class="headnote_text">
Inherent anticipation of method claims does not require that cited prior art reference describe actual performance of claimed method, although it does require more than &ldquo;invitation to investigate&rdquo;; in present case, method claims in patent application directed to inhibitors of renin-angiotensin system, which require, in pertinent part, that method be used &ldquo;for the treatment or prevention of stroke or its recurrence,&rdquo; are inherently anticipated by prior art reference describing design for study of RAS inhibitor ramipril in prevention of cardiovascular events such as myocardial infarction or stroke, since study's protocol for administration of ramipril was advanced stage of testing designed to secure regulatory approval, not mere abstract theory, and applicants admit that authors of study could have obtained claims at issue based on that reference.</div>
</div>
</div>
<script type="text/javascript">
					jQuery(function($) {
						$('#toggle_headnotes_button').click(document_toggleHeadnoteVisibility);
					});
				</script><div id="para2" printdualcolumn="true"><p>
<span CLASS="page_no" data-cite="677 f 3d 1376" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1376" data-primary-citation="677 F.3d 1375">[*1376]</span> 
J. Mark Pohl, Pharmaceutical Patent Attorneys, LLC, of Morristown, NJ,
argued for appellants.
</p></div>
<div id="para2" printdualcolumn="true"><p>
Scott C. Weidenfeller, Associate Solicitor, Office of the Solicitor, United
States Patent and Trademark Office, of Alexandria, VA, argued for appellee.
With him on the brief were Raymond T. Chen, Solicitor, and Frances M. Lynch,
Associate Solicitor.
</p></div>
<div id="para2" printdualcolumn="true"><p>
Before LOURIE, DYK, and PROST, Circuit Judges.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
DYK, Circuit Judge.
</p></div>
<div id="contentOpinion" printdualcolumn="true">
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Opinion for the court filed by Circuit Judge DYK.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Dissenting opinion filed by Circuit Judge LOURIE.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Hugh Edward Montgomery, John Francis Martin, and Jorge Daniel Erusalimsky
(collectively, "Montgomery") appeal from a decision of the Board of Patent
Appeals and Interferences ("Board") affirming the examiner's rejection of
claims 42, 43, and 45 of U.S. Patent Application Serial No. 11/118,824 (the
`"<a href="/s/opinion/0a7288dab8b2e0e9ee9dc2d8937d7419/document/XG00500944311GJ?jcsearch=uspa%2011118824&amp;summary=yes#jcite">824 application</a>") as anticipated. <i>See Ex parte Montgomery ("Rehearing</i>
<i>Decision</i>"), No. <cite>2011-000170</cite>, <cite>2011 WL 514316</cite> (B.P.A.I. Feb. 10, 2011); <i>Ex</i>
<i>parte Montgomery ("Board Decision</i>"), No. <cite>2011-000170</cite>, <cite>2010 WL 4719114</cite>
(B.P.A.I. Nov. 18, 2010). We affirm.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  BACKGROUND
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Montgomery filed the '824 application on April 29, 2005, claiming priority
to United Kingdom applications No. 9722026.3, filed October 17, 1997, and
No. 9810855.8, filed May 20, 1998. The application is directed to inhibitors
of the reninangiotensin system ("RAS"), which is "important in the
maintenance and control of blood pressure as well as the regulation of salt
and water metabolism." J.A. 225. As the '824 application's specification
notes, RAS inhibitors have been administered to treat high blood pressure,
known as hypertension,
<span CLASS="page_no" data-cite="677 f 3d 1377" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1377" data-primary-citation="677 F.3d 1375">[*1377]</span> 
and "it is preferred . . . to use in the practice of the invention any of
the known RAS inhibitors which are either on the market or under
investigation for their antihypertensive effects." J.A. 231-32. These "known
RAS inhibitors" include angiotensin-converting enzyme inhibitors ("ACE
inhibitors") such as ramipril. J.A. 232. The specification is largely
directed to treating wasting diseases such as cachexia, and to improving
cardiovascular fitness and physical endurance. Stroke treatment and
prevention is only mentioned in passing as a potential object of this
invention. <i>See</i>J.A. 230-31.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The claims at issue recite administering RAS inhibitors to patients
diagnosed as in need of stroke treatment or prevention:
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
      42. A <i>method for the treatment or prevention of stroke or its</i>
    <i>recurrence</i>, wherein said method comprises <i>administering, to a</i>
    <i>patient diagnosed as in need of such treatment or prevention</i>, an
    inhibitor of the rennin-angiotensin system, said inhibitor having a
    <i>Clog</i>P of greater than about 1.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
      43. The method as claimed in claim 42, wherein the inhibitor of
    the rennin-an-giotensin system comprises at least one inhibitor of
    angiotensin-converting enzyme.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
      45. The method as claimed in claim 43, wherein the inhibitor of
    angiotensin-converting enzyme comprises ramipril.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  J.A. 1 (emphases added). The examiner rejected these claims as anticipated
by each of four prior art references: <span CLASS="page_no" data-cite="2012 bl 112237 p 2" data-cite-type="Bloomberg" data-cite-pageno="2" data-primary-citation="">[***2]</span> AIRE,<a HREF="#fn100" name="fnref_fn100">[fn1]</a> Frampton,<a HREF="#fn200" name="fnref_fn200">[fn2]</a> HOPE,<a HREF="#fn300" name="fnref_fn300">[fn3]</a>
and Gohlke<a HREF="#fn400" name="fnref_fn400">[fn4]</a> (as evidenced by Richer<a HREF="#fn500" name="fnref_fn500">[fn5]</a>), all of which describe
the administration of ramipril to subjects at risk of stroke.<a HREF="#fn600" name="fnref_fn600">[fn6]</a>
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Hypertension is a known risk factor for stroke. <i>Board Decision</i>,
<cite>2010 WL 4719114</cite>, at *4. AIRE describes a study in which about 2000 "patients
who had shown clinical evidence <span CLASS="page_no" data-cite="102 uspq 2d 1883" data-cite-type="ReporterOfDecisions" data-cite-pageno="1883" data-primary-citation="102 U.S.P.Q.2d 1881">[**1883]</span> of heart failure," many of whom suffered
from hypertension, were treated with ramipril or a placebo. AIRE at 821-22.
In particular, 289 (29%) of the patients receiving ramipril had
hypertension. <i>Id.</i>at 822. The study found "overall a 27% reduction in the
risk of death" and a 19% reduction in the risk of "the first validated event
in any individual patient &mdash; namely, death, reinfarction, stroke, or
development of severe/resistant heart failure,"
<span CLASS="page_no" data-cite="677 f 3d 1378" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1378" data-primary-citation="677 F.3d 1375">[*1378]</span> 
and both results were "highly significant statistically." <i>Id.</i>at 824. The
data on stroke were not statistically significant: "The incidence of stroke
was higher in the active drug group but the numbers were small and an
adverse effect of the drug can be neither supported nor refuted." <i>Id.</i>at 826.
Frampton summarizes AIRE and other "large-scale noncomparative studies" and
explains that "[t]he antihypertensive efficacy of ramipril has been
confirmed" by these studies. J.A. 45.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  HOPE describes the design of "a large, simple randomized trial of . . .
ramipril . . . and vitamin E . . . in the prevention of myocardial
infarction, stroke, or cardiovascular death," which recruited "[o]ver 9000
[patients] at high risk for cardiovascular events such as myocardial
infarction and stroke." HOPE at 127. HOPE discloses that at the time of its
publication, all 9541 patients had been randomized and had been receiving
ramipril or a placebo for at least one month.<a HREF="#fn700" name="fnref_fn700">[fn7]</a> (The HOPE study
ultimately found that patients receiving ramipril had a statistically
significant reduction in the risk of stroke,<a HREF="#fn800" name="fnref_fn800">[fn8]</a> but these results were not
published until after Montgomery's priority date and thus are irrelevant to
an anticipation analysis.)
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Finally, Gohlke describes a study of "the effects of . . . ramipril on
functional and biochemical cardiac parameters in stroke-prone spontaneously
hypertensive rats," which found that the treatment "improves cardiac
function even at low doses." Gohlke at 411. Richer further explains that
"[t]he stroke-prone spontaneously hypertensive rat . . . is an experimental
model that has been widely used to investigate the potential preventive
effects vs stroke and mortality of numerous antihypertensive agents. Among
the latter, angiotensin I-converting enzyme inhibitors, angiotensin II
ATI-receptor blockers and calcium antagonists have proven to be very
effective." J.A. 85.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The Board affirmed the examiner's rejection of all three claims as
anticipated by each of these prior art references. <i>Board Decision</i>,
<cite>2010 WL 4719114</cite>, at *12. The Board found that claim 42 has two elements: (1)
"to administer an inhibitor of the rennin-angiotensin system," and (2) "the
patient population receiving the inhibitor . . . encompasses patients
diagnosed as required stroke treatment or prevention." <i></i><cite>Id.at *4</cite>. The Board
explained that each reference teaches administration of ramipril to
stroke-<span CLASS="page_no" data-cite="2012 bl 112237 p 3" data-cite-type="Bloomberg" data-cite-pageno="3" data-primary-citation="">[***3]</span> prone patients: "AIRE identified patients with hypertension who are
known to be at risk of stroke, and treated this patient population with
ramipril," "Frampton teaches treatment of hypertensive patients with
ramipril" (where "hypertension is a known `risk factor for stroke'"), "the
HOPE study was clearly enabled to treat patients, including patients with
previous stroke, with ramipril,"
<span CLASS="page_no" data-cite="677 f 3d 1379" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1379" data-primary-citation="677 F.3d 1375">[*1379]</span> 
and Gohlke "identi[ies] the rats, here reasonably interpreted as the
patients, as `stroke-prone' and then teaches administering ramipril to the
rats." <i></i><cite>Id.at *4</cite>, 7, 9, 10-11.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  While the Board did not rule directly on whether Montgomery's claims
required that the administration be effective at treating or preventing
stroke, it appeared to assume that they did include such a requirement. The
Board rejected Montgomery's argument that none of the references
demonstrated that ramipril actually treats or prevents stroke, noting that
ramipril inherently treats or prevents stroke, and "[i]t matters not that
those of ordinary skill heretofore may not have recognized these inherent
characteristics." <i></i><cite>Id.at *4</cite> (quoting <i>In re Cruciferous Sprout Litig.</i>,
<a href="/s/opinion/0a7288dab8b2e0e9ee9dc2d8937d7419/document/XE4P59?jcsearch=301%20f%203d%201343&amp;summary=yes#jcite">301 F.3d 1343</a>, <a href="/s/opinion/0a7288dab8b2e0e9ee9dc2d8937d7419/document/XE4P59?jcsearch=301%20f%203d%201343&amp;summary=yes#jcite">1350</a> (Fed.Cir.2002)) (internal quotation marks omitted).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Montgomery filed a request for rehearing, arguing that AIRE and Frampton
did not teach administration to patients diagnosed as at risk <span CLASS="page_no" data-cite="102 uspq 2d 1884" data-cite-type="ReporterOfDecisions" data-cite-pageno="1884" data-primary-citation="102 U.S.P.Q.2d 1881">[**1884]</span> of stroke
because stroke is only one of the afflictions caused by hypertension; that
HOPE was merely a proposal for future research that was not enabled; and
that Gohlke could not anticipate because the claim term "patient" should be
limited to human beings. <i>See</i>Request for Rehearing, <i>In re Montgomery</i>, No.
<cite>2011-000170</cite> (B.P.A.I. Jan. 24, 2011). The Board declined to modify its
original decision. <i>Rehearing Decision</i>, <cite>2011 WL 514316</cite>, at *4. The Board
noted that "[i]t does not matter whether [AIRE] appreciated that . . .
treatment [with ramipril], which was undisputedly actually performed on 289
patients with hypertension and 230 patients with previous myocardial
infarct, would treat or prevent stroke," and that HOPE "was clearly enabled
to treat patients, including patients with previous stroke, with ramipril."
<i>Id.</i>at *2.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Montgomery timely appealed, and we have jurisdiction pursuant to
<a href="/s/opinion/0a7288dab8b2e0e9ee9dc2d8937d7419/document/XEIMUG003?jcsearch=28%20U.S.C.%20%201295(a)(4)(A)&amp;summary=yes#jcite">28 U.S.C. &sect; 1295</a>(a)(4)(A).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  DISCUSSION
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Under the Administrative Procedure Act, we review the Board's legal
conclusions without deference and set aside conclusions that are "not in
accordance with law," and we review its findings of fact to determine if
they are "unsupported by substantial evidence." <a href="/s/opinion/0a7288dab8b2e0e9ee9dc2d8937d7419/document/XEGP3C003?jcsearch=5%20U.S.C.%20%20706(2)&amp;summary=yes#jcite">5 U.S.C. &sect; 706</a>(2); <i>see</i>
<i>Dickinson v. Zurko</i>, <a href="/s/opinion/0a7288dab8b2e0e9ee9dc2d8937d7419/document/X2T5FN?jcsearch=527%20us%20150&amp;summary=yes#jcite">527 U.S. 150</a>, <a href="/s/opinion/0a7288dab8b2e0e9ee9dc2d8937d7419/document/X2T5FN?jcsearch=527%20us%20150&amp;summary=yes#jcite">162</a> &mdash; 65, <a href="/s/opinion/0a7288dab8b2e0e9ee9dc2d8937d7419/document/X2T5FN?jcsearch=119%20supreme%20court%201816&amp;summary=yes#jcite">119 S.Ct. 1816</a>, <a href="/s/opinion/0a7288dab8b2e0e9ee9dc2d8937d7419/document/X2T5FN?jcsearch=144%20l%20ed%202d%20143&amp;summary=yes#jcite">144 L.Ed.2d 143</a>
(1999).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  "Determining whether claims are anticipated involves a two-step analysis.
The first step involves construction of the claims of the patent at issue.
Claim construction is a question of law reviewed <i>de novo." In re Aoyama</i>,
<a href="/s/opinion/0a7288dab8b2e0e9ee9dc2d8937d7419/document/X1G4UIA003?jcsearch=656%20f%203d%201293&amp;summary=yes#jcite">656 F.3d 1293</a>, <a href="/s/opinion/0a7288dab8b2e0e9ee9dc2d8937d7419/document/X1G4UIA003?jcsearch=656%20f%203d%201293&amp;summary=yes#jcite">1296</a> (Fed.Cir.2011). "During examination, `claims . . . are
to be given their broadest reasonable interpretation consistent with the
specification, and . . . claim language should be read in light of the
specification as it would be interpreted by one of ordinary skill in the
art.'" <i>In re Am. Acad, of Sci. Tech Ctr.</i>, <a href="/s/opinion/0a7288dab8b2e0e9ee9dc2d8937d7419/document/XALCD6?jcsearch=367%20f%203d%201359&amp;summary=yes#jcite">367 F.3d 1359</a>, <a href="/s/opinion/0a7288dab8b2e0e9ee9dc2d8937d7419/document/XALCD6?jcsearch=367%20f%203d%201359&amp;summary=yes#jcite">1364</a> (Fed.
Cir.2004) (alteration in original) (quoting <i>In re Bond</i>, <a href="/s/opinion/0a7288dab8b2e0e9ee9dc2d8937d7419/document/X33HS5?jcsearch=910%20f%202d%20831&amp;summary=yes#jcite">910 F.2d 831</a>, <a href="/s/opinion/0a7288dab8b2e0e9ee9dc2d8937d7419/document/X33HS5?jcsearch=910%20f%202d%20831&amp;summary=yes#jcite">833</a>
(Fed.Cir.1990)). The broadest <span CLASS="page_no" data-cite="2012 bl 112237 p 4" data-cite-type="Bloomberg" data-cite-pageno="4" data-primary-citation="">[***4]</span> reasonable interpretation, like claim
construction in the infringement context, is a question of law that we
review de novo. <i>In re NTP, Inc.</i>, <a href="/s/opinion/0a7288dab8b2e0e9ee9dc2d8937d7419/document/X1FV5AC003?jcsearch=654%20f%203d%201268&amp;summary=yes#jcite">654 F.3d 1268</a>, <a href="/s/opinion/0a7288dab8b2e0e9ee9dc2d8937d7419/document/X1FV5AC003?jcsearch=654%20f%203d%201268&amp;summary=yes#jcite">1274</a> (Fed.Cir.2011). "The
second step [of an anticipation analysis] involves comparing the claims to
the prior art. Anticipation is a question of fact reviewed for substantial
evidence." <i>In re Aoyama</i>, <a href="/s/opinion/0a7288dab8b2e0e9ee9dc2d8937d7419/document/X1G4UIA003?jcsearch=656%20f%203d%201293&amp;summary=yes#jcite">656 F.3d at 1296</a>. A prior art reference anticipates
a patent claim under <a href="/s/opinion/0a7288dab8b2e0e9ee9dc2d8937d7419/document/XEIVVC003?jcsearch=35%20U.S.C.%20%20102(b)&amp;summary=yes#jcite">35 U.S.C. &sect; 102</a>(b) if it discloses every claim
limitation. <i>Verizon Servs. Corp. v. Cox Fibernet Va., Inc.</i>, <a href="/s/opinion/0a7288dab8b2e0e9ee9dc2d8937d7419/document/X1D25KU003?jcsearch=602%20f%203d%201325&amp;summary=yes#jcite">602 F.3d 1325</a>,
<a href="/s/opinion/0a7288dab8b2e0e9ee9dc2d8937d7419/document/X1D25KU003?jcsearch=602%20f%203d%201325&amp;summary=yes#jcite">1336-37</a> (Fed.Cir.2010). A reference may anticipate inherently if a claim
limitation
<span CLASS="page_no" data-cite="677 f 3d 1380" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1380" data-primary-citation="677 F.3d 1375">[*1380]</span> 
that is not expressly disclosed "is necessarily present, or inherent, in the
single anticipating reference." <i></i><a href="/s/opinion/0a7288dab8b2e0e9ee9dc2d8937d7419/document/X1D25KU003?jcsearch=602%20F.3d%201325&amp;summary=yes#jcite">Id.at 1337</a> (quoting <i>Schering Corp. v. Geneva</i>
<i>Pharm., Inc.</i>, <a href="/s/opinion/0a7288dab8b2e0e9ee9dc2d8937d7419/document/X6A0JG?jcsearch=339%20f%203d%201373&amp;summary=yes#jcite">339 F.3d 1373</a>, <a href="/s/opinion/0a7288dab8b2e0e9ee9dc2d8937d7419/document/X6A0JG?jcsearch=339%20f%203d%201373&amp;summary=yes#jcite">1377</a> (Fed.Cir.2003)) (internal quotation mark
omitted). The inherent result must inevitably result from the disclosed
steps; "[i]nherency . . . may not be established by probabilities or
possibilities." <i>Bettcher Indus., Inc. v. Bunzl USA Inc.</i>, <a href="/s/opinion/0a7288dab8b2e0e9ee9dc2d8937d7419/document/X1GGM0K003?jcsearch=661%20f%203d%20629&amp;summary=yes#jcite">661 F.3d 629</a>, <a href="/s/opinion/0a7288dab8b2e0e9ee9dc2d8937d7419/document/X1GGM0K003?jcsearch=661%20f%203d%20629&amp;summary=yes#jcite">639</a>
(Fed.Cir.2011) (quoting <i>In re Oelrich</i>, <a href="/s/opinion/0a7288dab8b2e0e9ee9dc2d8937d7419/document/XII0ON?jcsearch=666%20f%202d%20578&amp;summary=yes#jcite">666 F.2d 578</a>, <a href="/s/opinion/0a7288dab8b2e0e9ee9dc2d8937d7419/document/XII0ON?jcsearch=666%20f%202d%20578&amp;summary=yes#jcite">581</a> (CCPA 1981)).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The contested elements of claim 45 are the administration of ramipril (1)
"to a patient diagnosed as in need of [stroke] treatment or prevention," (2)
where such administration is "for the treatment or prevention of stroke or
its recurrence."<a HREF="#fn900" name="fnref_fn900">[fn9]</a> We thus determine de novo the broadest reasonable
interpretation of each of these requirements. Because we conclude that HOPE
discloses both requirements, we need not address Montgomery's arguments
concerning AIRE, Frampton, and Gohlke.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  We first examine the requirement that the administration be "to a patient
diagnosed as in need of [stroke] treatment or prevention." Montgomery does
not contest that the patients in HOPE satisfy this claim requirement. HOPE
explicitly disclosed the administration of ramipril to patients "at high
risk for cardiovascular events such as myocardial infarction and stroke,"
and the eligibility criteria included patients with previous stroke. HOPE at
127-28. We see no error in the Board's uncontested conclusion that HOPE
discloses the administration of ramipril to patients diagnosed as in need of
stroke treatment or prevention.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  We next turn to the preamble requirement that the method be "for the
treatment or prevention of stroke or its recurrence." The Board did not rule
directly on whether the broadest reasonable interpretation of the claims
required that the treatment or prevention <span CLASS="page_no" data-cite="102 uspq 2d 1885" data-cite-type="ReporterOfDecisions" data-cite-pageno="1885" data-primary-citation="102 U.S.P.Q.2d 1881">[**1885]</span> be effective or whether it was
sufficient that the administration be designed to treat or prevent
stroke.<a HREF="#fn1000" name="fnref_fn1000">[fn10]</a> But in resting the decision on inherency, the
Board appeared to assume that the patent included an efficacy requirement.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  We are skeptical that a proper interpretation of the claims would include
an efficacy requirement. In <i>Bristol-Myers Squibb Co. v. Ben Venue</i>
<i>Laboratories, Inc.</i>, we construed a similar method-of-treatment claim &mdash;
involving "[a] method for reducing hematologic toxicity" by administering
taxol to a cancer patient &mdash; and held that it "merely express[ed] a purpose
of reducing hematologic toxicity" rather than requiring a particular result.
<a href="/s/opinion/0a7288dab8b2e0e9ee9dc2d8937d7419/document/X50LR9?jcsearch=246%20f%203d%201368&amp;summary=yes#jcite">246 F.3d 1368</a>, <a href="/s/opinion/0a7288dab8b2e0e9ee9dc2d8937d7419/document/X50LR9?jcsearch=246%20f%203d%201368&amp;summary=yes#jcite">1371</a>, <a href="/s/opinion/0a7288dab8b2e0e9ee9dc2d8937d7419/document/X50LR9?jcsearch=246%20f%203d%201368&amp;summary=yes#jcite">1375</a> (Fed.Cir.2001). Such a construction is even more
appropriate <span CLASS="page_no" data-cite="2012 bl 112237 p 5" data-cite-type="Bloomberg" data-cite-pageno="5" data-primary-citation="">[***5]</span> here in the examination context, where we apply the "broadest
reasonable interpretation
<span CLASS="page_no" data-cite="677 f 3d 1381" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1381" data-primary-citation="677 F.3d 1375">[*1381]</span> 
consistent with the specification." <i>In re Am. Acad. of Sci. Tech Ctr.</i>,
<a href="/s/opinion/0a7288dab8b2e0e9ee9dc2d8937d7419/document/XALCD6?jcsearch=367%20f%203d%201359&amp;summary=yes#jcite">367 F.3d at 1364</a>. Nothing in the '824 specification suggests that a narrower
construction is appropriate: the specification does not describe any studies
that show that RAS inhibitors are effective for stroke treatment or
prevention, <i>see</i>J.A. 224-52, thus also suggesting that the claims do not
incorporate such a requirement, <i>see Phillips v. AWH Corp.</i>, <a href="/s/opinion/0a7288dab8b2e0e9ee9dc2d8937d7419/document/X12HHT2003?jcsearch=415%20f%203d%201303&amp;summary=yes#jcite">415 F.3d 1303</a>,
<a href="/s/opinion/0a7288dab8b2e0e9ee9dc2d8937d7419/document/X12HHT2003?jcsearch=415%20f%203d%201303&amp;summary=yes#jcite">1315</a> (Fed. Cir.2005) (en banc) ("[C]laims must be read in view of the
specification, of which they are a part." (internal quotation marks
omitted)).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  <a id="headnote_ref_pq2-dec_915532" href="#headnote_pq2-dec_915532">[1]</a> We need not resolve this question, however, for we agree with the Board
that even if the claim includes an efficacy requirement, efficacy is
inherent in carrying out the claim steps. <i>See Rehearing Decision</i>,
<cite>2011 WL 514316</cite>, at *2. We agree with the dissent that a result is only
inherent if it inevitably flows from the prior art disclosure, but there is
no question here that treating stroke-prone patients with ramipril does in
fact inevitably treat or prevent stroke. And Montgomery does not dispute
that ramipril is in fact effective at preventing or treating stroke, which
is the entire premise of his patent.<a HREF="#fn1100" name="fnref_fn1100">[fn11]</a>
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  We have repeatedly held that "[n]ewly discovered results of known
processes directed to the same purpose are not patentable because such
results are inherent." <i>Bristol-Myers Squibb</i>, <a href="/s/opinion/0a7288dab8b2e0e9ee9dc2d8937d7419/document/X50LR9?jcsearch=246%20f%203d%201368&amp;summary=yes#jcite">246 F.3d at 1376</a>. As we stated
in <i>Cruciferous Sprout</i>, <a href="/s/opinion/0a7288dab8b2e0e9ee9dc2d8937d7419/document/XE4P59?jcsearch=301%20f%203d%201343&amp;summary=yes#jcite">301 F.3d at 1350</a>, "[i]t matters not that those of
ordinary skill heretofore may not have recognized the[] inherent
characteristics of the [prior art]."
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  In <i>King Pharmaceuticals, Inc. v. Eon Labs, Inc.</i>, <a href="/s/opinion/0a7288dab8b2e0e9ee9dc2d8937d7419/document/X1DP7R8003?jcsearch=616%20f%203d%201267&amp;summary=yes#jcite">616 F.3d 1267</a>, <a href="/s/opinion/0a7288dab8b2e0e9ee9dc2d8937d7419/document/X1DP7R8003?jcsearch=616%20f%203d%201267&amp;summary=yes#jcite">1270</a>
(Fed.Cir.2010), one of the claims covered "a method of increasing the oral
bioavailability of metaxalone" by "administering to the patient a
therapeutically effective amount of metaxalone in a pharmaceutical
composition with food." We noted that according to the patent itself, "the
natural result of taking metaxalone with food is an increase in the
bioavailability of the drug," and that "[t]he prior art discloses taking
metaxalone with food," so the preamble was "inherently anticipated." <i></i><a href="/s/opinion/0a7288dab8b2e0e9ee9dc2d8937d7419/document/X1DP7R8003?jcsearch=616%20F.3d%201267&amp;summary=yes#jcite">Id.at
1275-76</a>. Similarly, in <i>Cruciferous Sprout</i>, the claims at issue included "[a]
method of preparing a food product rich in glucosinolates, comprising
germinated cruciferous seeds . . . and harvesting sprouts prior to the
2-leaf stage, to form a food product comprising a plurality of sprouts."
<a href="/s/opinion/0a7288dab8b2e0e9ee9dc2d8937d7419/document/XE4P59?jcsearch=301%20f%203d%201343&amp;summary=yes#jcite">301 F.3d at 1345</a>. We agreed that "rich in glucosinolates" is a claim
limitation, but found the claims inherently anticipated because the patentee
merely recognized properties that "necessarily have existed as long as
sprouts themselves." <i></i><a href="/s/opinion/0a7288dab8b2e0e9ee9dc2d8937d7419/document/XE4P59?jcsearch=301%20F.3d%20at%201345&amp;summary=yes#jcite">Id.at 1347</a>, <a href="/s/opinion/0a7288dab8b2e0e9ee9dc2d8937d7419/document/XE4P59?jcsearch=1350&amp;summary=yes#jcite">1350</a>.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  HOPE discloses a protocol for the administration of ramipril to
stroke-prone patients, and administering ramipril to stroke-prone patients
inevitably treats or prevents stroke. <i>See</i>HOPE at 127. Thus, HOPE inherently
anticipates the claims at issue.
<span CLASS="page_no" data-cite="102 uspq 2d 1886" data-cite-type="ReporterOfDecisions" data-cite-pageno="1886" data-primary-citation="102 U.S.P.Q.2d 1881">[**1886]</span> </p></div>
<span CLASS="page_no" data-cite="677 f 3d 1382" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1382" data-primary-citation="677 F.3d 1375">[*1382]</span> <div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  <a id="headnote_ref_pq2-dec_915533" href="#headnote_pq2-dec_915533">[2]</a> However, Montgomery urges that inherent anticipation requires that
the claimed method have been actually performed, and that HOPE
does not disclose actual performance of the method. This is
not correct; HOPE reveals the <span CLASS="page_no" data-cite="2012 bl 112237 p 6" data-cite-type="Bloomberg" data-cite-pageno="6" data-primary-citation="">[***6]</span> actual administration of ramipril
for treatment or prevention of stroke.<a HREF="#fn1200" name="fnref_fn1200">[fn12]</a>
In any event, even if HOPE merely proposed the administration of
ramipril for treatment or prevention of stroke (without actually doing so),
it would still anticipate. Our cases have expressly rejected Montgomery's
argument. For example, in <i>Schering</i>, <a href="/s/opinion/0a7288dab8b2e0e9ee9dc2d8937d7419/document/X6A0JG?jcsearch=339%20f%203d%201373&amp;summary=yes#jcite">339 F.3d at 1381</a>, we held that a prior
art patent that disclosed administering loratadine to a patient inherently
anticipated a patent for a metabolite of loratadine because the inherent
result of administering loratadine to a patient is the formation of the
metabolite. We stated that anticipation "requires only an enabling
disclosure," not "actual creation or reduction to practice," so that "actual
administration of loratadine to patients [in the prior art] is irrelevant" &mdash;
the prior art patent inherently anticipated as long as it "disclose[d] in an
enabling manner the administration of loratadine to patients." <i></i><a href="/s/opinion/0a7288dab8b2e0e9ee9dc2d8937d7419/document/X6A0JG?jcsearch=339%20F.3d%20at%201381&amp;summary=yes#jcite">Id.at 1380</a>;
<i>see also Smith-Kline Beecham Corp. v. Apotex Corp.</i>, <a href="/s/opinion/0a7288dab8b2e0e9ee9dc2d8937d7419/document/XFVK60?jcsearch=403%20f%203d%201331&amp;summary=yes#jcite">403 F.3d 1331</a>, <a href="/s/opinion/0a7288dab8b2e0e9ee9dc2d8937d7419/document/XFVK60?jcsearch=403%20f%203d%201331&amp;summary=yes#jcite">1343-44</a>
(Fed.Cir.2005) (holding a chemical patent inherently anticipated and stating
that it was irrelevant whether the inherently disclosed chemical was ever
actually produced).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  To be sure, as the dissent points out, "[a]n invitation to investigate is
not an inherent disclosure." <i>Metabolite Labs., Inc. v. Lab. Corp. of Am.</i>
<i>Holdings</i>, <a href="/s/opinion/0a7288dab8b2e0e9ee9dc2d8937d7419/document/XAPLKN?jcsearch=370%20f%203d%201354&amp;summary=yes#jcite">370 F.3d 1354</a>, <a href="/s/opinion/0a7288dab8b2e0e9ee9dc2d8937d7419/document/XAPLKN?jcsearch=370%20f%203d%201354&amp;summary=yes#jcite">1367</a> (Fed.Cir.2004).<a HREF="#fn1300" name="fnref_fn1300">[fn13]</a> But HOPE's protocol for
the administration of ramipril is far from an abstract theory &mdash; it is an
advanced stage of testing designed to secure regulatory approval. HOPE was
designed to obtain data for submission to regulatory agencies on the effect
of ramipril on cardiovascular diseases including stroke based on substantial
evidence that ramipril improved cardiovascular health, including by treating
stroke risk factors such as hypertension. <i>See</i>HOPE at 128. It is well
established that a patent may be secured, and typically is secured, before
the conclusion of clinical trials. <i>See Eli Lilly &amp; Co. v. Teva Pharm. USA</i>
<i>Inc.</i>, <a href="/s/opinion/0a7288dab8b2e0e9ee9dc2d8937d7419/document/X1E54SG003?jcsearch=619%20f%203d%201329&amp;summary=yes#jcite">619 F.3d 1329</a>, <a href="/s/opinion/0a7288dab8b2e0e9ee9dc2d8937d7419/document/X1E54SG003?jcsearch=619%20f%203d%201329&amp;summary=yes#jcite">1335</a>, <a href="/s/opinion/0a7288dab8b2e0e9ee9dc2d8937d7419/document/X1E54SG003?jcsearch=619%20f%203d%201329&amp;summary=yes#jcite">1343</a> (Fed.Cir.2010) (rejecting an enablement
challenge to patents that were filed while clinical trial results were
pending); <i>Manual of Patent Examining Procedure</i>&sect; 2107.03 (8th ed., rev.6,
Sept. 2007) ("[I]f an applicant has initiated human clinical trials for a
therapeutic product or process, [Patent &amp; Trademark] Office personnel should
presume that the
<span CLASS="page_no" data-cite="677 f 3d 1383" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1383" data-primary-citation="677 F.3d 1375">[*1383]</span> 
applicant has established that the subject matter of that trial is
reasonably predictive of having the asserted therapeutic utility."). In all
relevant respects, HOPE is identical to the patent itself, which does not
disclose actual results from the administration of ramipril for these
purposes.<a HREF="#fn1400" name="fnref_fn1400">[fn14]</a> Montgomery conceded at oral argument that HOPE's authors
could have obtained the patent claims at issue based the HOPE reference, so
it cannot be that this reference fails to anticipate.<a HREF="#fn1500" name="fnref_fn1500">[fn15]</a>
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  <span CLASS="page_no" data-cite="102 uspq 2d 1887" data-cite-type="ReporterOfDecisions" data-cite-pageno="1887" data-primary-citation="102 U.S.P.Q.2d 1881">[**1887]</span> We thus affirm the rejection of claims 42, 43, and 45 of the '824
application as anticipated by HOPE. Because we affirm the Board's decision
on this ground, we need not reach the issue of whether the claims are
anticipated by the other prior art considered by the Board.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  <b>AFFIRMED</b>
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  COSTS
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  No costs.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<span class="fr"><a HREF="#fnref_fn100" name="fn100">[fn1]</a></span> The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators,
<i>Effect of Ramipril on Mortality and Morbidity of Survivors of Acute</i>
<i>Myocardial Infarction with Clinical Evidence of Heart Failure</i>, 342 Lancet
821 (1993) ("AIRE"); J.A. 7-14.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<span class="fr"><a HREF="#fnref_fn200" name="fn200">[fn2]</a></span> James E. Frampton &amp; David H. Peters, <i>Ramipril: An Updated Review of</i>
<i>Its Therapeutic Use in Essential Hypertension and Heart Failure</i>, 49 Drugs
440 (1995) (abstract) ("Frampton"); J.A. 45-48.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<span class="fr"><a HREF="#fnref_fn300" name="fn300">[fn3]</a></span> The HOPE Study Investigators, <i>The HOPE (Heart Outcomes Prevention</i>
<i>Evaluation) Study: The Design of a Large, Simple Randomized Trial of an</i>
<i>Angiotensin-Converting Enzyme Inhibitor (Ramipril) and Vitamin E in Patients</i>
<i>at High Risk of Cardiovascular Events</i>, 12 Can. J. Cardiology 127 (1996)
("HOPE"); J.A. 58-68.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<span class="fr"><a HREF="#fnref_fn400" name="fn400">[fn4]</a></span> Peter Gohlke et al., <i>Angiotensin-Converting Enzyme Inhibition Improves</i>
<i>Cardiac Function</i>, 23 Hypertension 411 (1994) ("Gohlke"); J.A. 49-56.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<span class="fr"><a HREF="#fnref_fn500" name="fn500">[fn5]</a></span> C. Richer et al., <i>Antihypertensive Drugs in the Stroke-Prone</i>
<i>Spontaneously Hypertensive Rat</i>, 19 Clinical &amp; Experimental Hypertension 925
(1997) (abstract), <i>available at</i>http://www. ncbi.nlm.nih.gov/pubmed/9247765
("Richer"); J.A. 85.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<span class="fr"><a HREF="#fnref_fn600" name="fn600">[fn6]</a></span> As the claims themselves state, ramipril is "an inhibitor of the
rennin-angiotensin system" and an "inhibitor of angiotensin-converting
enzyme." J.A. 1. And the Board found, and Montgomery does not contest, that
"[t]he ClogP properties recited in the claim[s] [are] inherently present in
ramipril." <i>Board Decision</i>, <cite>2010 WL 4719114</cite>, at *2.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<span class="fr"><a HREF="#fnref_fn700" name="fn700">[fn7]</a></span> HOPE was published in February 1996, and "[a]s of January 1, 1996 the
study [had] completed randomizing 9541 patients." <i>Id.</i>at 134. Patients were
"given seven to 10 days of 2.5 mg active ramipril" prior to randomization.
<i>Id.</i>at 132. Each patient was then randomized individually "by a telephone
call to a central office," after which "the patient [was] randomized to
ramipril (2.5 mg for one week, then 5 mg every day for three weeks) or
matching placebo," and was "given a date for a first follow-up visit (one
month plus or minus one week) after which the dose of ramipril [was]
increased to 10 mg daily." <i>Id.</i>This protocol demonstrates that prior to
HOPE's publication, every patient randomized to ramipril received at least
2.5 mg ramipril daily for one week and 5 mg daily for three weeks.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<span class="fr"><a HREF="#fnref_fn800" name="fn800">[fn8]</a></span> <i>See</i>The Heart Outcomes Prevention Evaluation Study Investigators,
<i>Effects of an Angiotensin-Converting-Enzyme Inhibitor, Ramipril, on</i>
<i>Cardiovascular Events in High-Risk Patients</i>, 342 New Eng. J. Med. 145, 148
tbl. 3 (2000).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<span class="fr"><a HREF="#fnref_fn900" name="fn900">[fn9]</a></span> Montgomery does not dispute that a prior art reference that
anticipates claim 45 (describing the administration of ramipril) necessarily
anticipates claims 43 (describing the administration of "at least one
inhibitor of angiotensin-converting enzyme") and claim 42 (describing the
administration of "an inhibitor of the rennin-angiotensin system, said
inhibitor having a <i>Clog</i>P of greater than about 1").
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<span class="fr"><a HREF="#fnref_fn1000" name="fn1000">[fn10]</a></span> The Board at first seemed to assume that efficacy was not a
requirement by not including efficacy in its description of the "two
elements" of the claims and by stating that "[a]ll that is required by
claims 42, 43 and 45 is identifying a patient in need of the treatment, and
administering ramipril to that patient," with no mention of efficacy. <i>Board</i>
<i>Decision</i>, <cite>2010 WL 4719114</cite>, at *4, *9. But the Board then referred to the
"preamble requirement of the claim to treat or prevent stroke," <i>id.</i>at *9,
suggesting that efficacy is a requirement.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<span class="fr"><a HREF="#fnref_fn1100" name="fn1100">[fn11]</a></span> Montgomery contends that AIRE teaches that ramipril increases the
risk of stroke because 2.5% of patients receiving ramipril suffered a stroke
compared with 1.7% of patients receiving the placebo. As discussed
previously, however, these results were not statistically significant, so
AIRE does not teach anything about the correlation between ramipril and
stroke risk; indeed, AIRE explicitly states that "an adverse effect of the
drug can be neither supported nor refuted." AIRE at 826. In any case, "the
question whether a reference `teaches away' from the invention is
inapplicable to an anticipation analysis." <i>Bristol-Myers Squibb</i>,
<a href="/s/opinion/0a7288dab8b2e0e9ee9dc2d8937d7419/document/X50LR9?jcsearch=246%20f%203d%201368&amp;summary=yes#jcite">246 F.3d at 1378</a> (quoting <i>Celeritas Techs., Ltd. v. Rockwell Int'l Corp.</i>,
<a href="/s/opinion/0a7288dab8b2e0e9ee9dc2d8937d7419/document/XACBVQ?jcsearch=150%20f%203d%201354&amp;summary=yes#jcite">150 F.3d 1354</a>, <a href="/s/opinion/0a7288dab8b2e0e9ee9dc2d8937d7419/document/XACBVQ?jcsearch=150%20f%203d%201354&amp;summary=yes#jcite">1361</a> (Fed.Cir.1998)) (internal quotation mark omitted).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<span class="fr"><a HREF="#fnref_fn1200" name="fn1200">[fn12]</a></span> Montgomery argues that HOPE only involved actual administration of
low dosages of ramipril, and that HOPE fails to disclose actual
administration in an amount sufficient for treatment or prevention. We
disagree. Before HOPE's publication date, all the patients in the HOPE study
were given "seven to 10 days of 2.5 mg active ramipril," and the patients
randomized to ramipril received "2.5 mg [ramipril] for one week, then 5 mg
every day for three weeks." HOPE at 132. Moreover, Frampton discloses that
"large-scale noncomparative studies" showed that "85% of patients with mild
to moderate essential hypertension have responded successfully to treatment
with ramipril 2.5 or 5 mg/day." J.A. 45. Thus, even if the HOPE authors did
not appreciate it, their actual administration of ramipril treated or
ameliorated hypertension, which as Montgomery acknowledges, is a risk factor
for stroke. In effect, therefore, HOPE inherently discloses reducing the
risk of stroke (i.e., teaches "stroke prevention") and thus inherently
anticipates the claims at issue.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<span class="fr"><a HREF="#fnref_fn1300" name="fn1300">[fn13]</a></span> For example, a document that recited administration of all known
compounds for treatment of all known diseases, with no evidence that any of
these treatments would be effective, would not inherently anticipate all
method-of-treatment claims involving those compounds and diseases.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<span class="fr"><a HREF="#fnref_fn1400" name="fn1400">[fn14]</a></span> Montgomery's specification disclosed small randomized trials of the
effect of losartan on muscle fatigue in military recruits and the effect of
enalapril on cachexia (wasting disease) in patients with heart failure.
<i>See</i>J.A. 247-52. The specification does not disclose any clinical studies
showing the effect of ACE inhibitors on stroke, nor does it disclose any
plans for such studies. In this respect, Montgomery's specification teaches
even less than HOPE does about the administration of ramipril for stroke
treatment or prevention.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<span class="fr"><a HREF="#fnref_fn1500" name="fn1500">[fn15]</a></span> Oral Argument at 10:24, <i>available at</i>http://
www.cafc.uscourts.gov/oral-argument-recordings/2011-1376/all (Court:
"Couldn't the HOPE people have gotten a patent based on the prior art
reference that's here? Couldn't they have applied and gotten a patent just
as you could have?" Counsel for Montgomery: "Yes, they could have."). We do
not have before us the question whether HOPE or Montgomery sufficiently
demonstrated utility to secure a patent. <i>See generally In re '<cite>318 Patent</cite></i>
<i>Infringement Litig.</i>, <a href="/s/opinion/0a7288dab8b2e0e9ee9dc2d8937d7419/document/X1BRAME003?jcsearch=583%20f%203d%201317&amp;summary=yes#jcite">583 F.3d 1317</a>, <a href="/s/opinion/0a7288dab8b2e0e9ee9dc2d8937d7419/document/X1BRAME003?jcsearch=583%20f%203d%201317&amp;summary=yes#jcite">1327</a> (Fed.Cir.2009) (holding that the
method of treatment claims at issue were not enabled "because the . . .
patent's application did not establish utility").
</p></div>
</div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  LOURIE, Circuit Judge, dissenting.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  I respectfully <span CLASS="page_no" data-cite="2012 bl 112237 p 7" data-cite-type="Bloomberg" data-cite-pageno="7" data-primary-citation="">[***7]</span> dissent from the majority's decision to affirm the
rejection by the United States Patent and Trademark Office ("PTO") of
pending claims 42, 43, and 45 for anticipation by inherency.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Inherency is a very tricky concept in patent law. Its salutary goal is to
prevent subject matter that is effectively in the public's possession from
being retrieved by a patent and withdrawn from the public domain. On the
other hand, its downside is withholding patent protection from that which
the public knew nothing about until a later inventor found it. A case cited
by the majority, <i>Schering Corp. v. Geneva Pharm., Inc.</i>, <a href="/s/opinion/0a7288dab8b2e0e9ee9dc2d8937d7419/document/X6A0JG?jcsearch=339%20f%203d%201373&amp;summary=yes#jcite">339 F.3d 1373</a>
(Fed.Cir.2003), illustrates the problem. A claimed compound not known to the
art was held to be anticipated by inherency when it was found to be a
metabolite of a prior art compound. Of course, many compounds administered
to humans and animals do metabolize in some manner rather than being fully
excreted as such. In <i>Schering</i>, however, the prior art (1) did not disclose
the later-claimed metabolite; (2) did not disclose any of the prior art
compound's metabolites; and (3) did not even disclose that the prior art
compound could metabolize upon administration. <i></i><a href="/s/opinion/0a7288dab8b2e0e9ee9dc2d8937d7419/document/X6A0JG?jcsearch=339%20F.3d%201373&amp;summary=yes#jcite">Id.at 1376</a>. On those facts,
the court nonetheless concluded that the later-claimed compound was
necessarily "in the public's possession," and thus was anticipated by
inherency. <i></i><a href="/s/opinion/0a7288dab8b2e0e9ee9dc2d8937d7419/document/X6A0JG?jcsearch=339%20F.3d%201373&amp;summary=yes#jcite">Id.at 1380</a> (internal quotation marks omitted); <i>see also Schering</i>
<i>Corp. v. Geneva Pharm., Inc.</i>, <a href="/s/opinion/0a7288dab8b2e0e9ee9dc2d8937d7419/document/X6B8CG?jcsearch=348%20f%203d%20992&amp;summary=yes#jcite">348 F.3d 992</a>, <a href="/s/opinion/0a7288dab8b2e0e9ee9dc2d8937d7419/document/X6B8CG?jcsearch=348%20f%203d%20992&amp;summary=yes#jcite">995-96</a> (Fed. Cir.2003) (Lourie,
J., dissenting from denial of petition for rehearing en banc).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  An unbounded concept of inherency, as <i>Schering</i>illustrates, threatens to
stymie
<span CLASS="page_no" data-cite="677 f 3d 1384" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1384" data-primary-citation="677 F.3d 1375">[*1384]</span> 
innovation by withdrawing from the realm of patentability that which has not
before been known, used, or benefited from. Properly understood,
anticipation by inherency is far more limited. <i>See Tilghman v. Proctor</i>,
<a href="/s/opinion/0a7288dab8b2e0e9ee9dc2d8937d7419/document/XM2DA3?jcsearch=102%20us%20707&amp;summary=yes#jcite">102 U.S. 707</a>, <a href="/s/opinion/0a7288dab8b2e0e9ee9dc2d8937d7419/document/XM2DA3?jcsearch=102%20us%20707&amp;summary=yes#jcite">711</a>, <a href="/s/opinion/0a7288dab8b2e0e9ee9dc2d8937d7419/document/XM2DA3?jcsearch=26%20l%20ed%20279&amp;summary=yes#jcite">26 L.Ed. 279</a> (1880) (declining to find anticipation by
inherency where a skilled artisan "certainly never derived the least hint"
of the claimed process from the prior art). Nevertheless, recent cases have
followed <i>Schering's</i>expansive holding. <i>See, e.g., Smith-Kline Beecham Corp.</i>
<i>v. Apotex Corp.</i>, <a href="/s/opinion/0a7288dab8b2e0e9ee9dc2d8937d7419/document/XFVK60?jcsearch=403%20f%203d%201331&amp;summary=yes#jcite">403 F.3d 1331</a>, <a href="/s/opinion/0a7288dab8b2e0e9ee9dc2d8937d7419/document/XFVK60?jcsearch=403%20f%203d%201331&amp;summary=yes#jcite">1343-44</a> (Fed.Cir.2005). Whether the
majority's holding in the present case will have a serious adverse effect on
innovation is unclear, but I believe that the majority has found inherency
where it does not exist.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The keystone of the inherency doctrine is inevitability. For anticipation
by inherency, a later-claimed invention must have necessarily resulted from
the practice of a prior art reference. Our precedent has been steadfast in
this strict requirement of inevitability. <i>See, e.g., Bettcher Indus., Inc.</i>
<i>v. Bunzl USA, Inc.</i>, <a href="/s/opinion/0a7288dab8b2e0e9ee9dc2d8937d7419/document/X1GGM0K003?jcsearch=661%20f%203d%20629&amp;summary=yes#jcite">661 F.3d 629</a>, <a href="/s/opinion/0a7288dab8b2e0e9ee9dc2d8937d7419/document/X1GGM0K003?jcsearch=661%20f%203d%20629&amp;summary=yes#jcite">639</a> (Fed.Cir.2011) ("Inherency . . . may
not be established by probabilities or possibilities. The mere fact that a
certain thing may result from a given set of circumstances is not
sufficient." (internal quotation marks omitted)); <i>Hansgirg v. Kemmer</i>,
26 CCPA 937, <a href="/s/opinion/0a7288dab8b2e0e9ee9dc2d8937d7419/document/X1VSRO?jcsearch=102%20f%202d%20212&amp;summary=yes#jcite">102 F.2d 212</a>, <a href="/s/opinion/0a7288dab8b2e0e9ee9dc2d8937d7419/document/X1VSRO?jcsearch=102%20f%202d%20212&amp;summary=yes#jcite">214</a> (1939) (same). Absent inevitability,
inherency does not follow even from a very high likelihood that a prior art
method will result in the claimed invention. <i>See, e.g., Glaxo Inc. v.</i>
<i>Novopharm Ltd.</i>, <a href="/s/opinion/0a7288dab8b2e0e9ee9dc2d8937d7419/document/XTMCTNQNB5G0?jcsearch=52%20f%203d%201043&amp;summary=yes#jcite">52 F.3d 1043</a>, <a href="/s/opinion/0a7288dab8b2e0e9ee9dc2d8937d7419/document/XTMCTNQNB5G0?jcsearch=52%20f%203d%201043&amp;summary=yes#jcite">1047</a> (Fed.Cir.1995) (holding that even though
the defendant's experts reproduced <span CLASS="page_no" data-cite="2012 bl 112237 p 8" data-cite-type="Bloomberg" data-cite-pageno="8" data-primary-citation="">[***8]</span> a prior art method "thirteen times and
each time they made [the claimed] crystals," the patentee's chemists twice
produced different crystals from the same method, thus precluding
inherency).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Were inevitability not required for inherency, a mere proposal for further
experimentation could anticipate a claimed invention. That is not the law,
however. There is nothing inevitable about a proposal. On this point, our
precedent is straightforward: "An invitation to investigate is not an
inherent disclosure." <i>Metabolite Labs., Inc. v. Lab. Corp. of Am. Holdings</i>,
<a href="/s/opinion/0a7288dab8b2e0e9ee9dc2d8937d7419/document/XAPLKN?jcsearch=370%20f%203d%201354&amp;summary=yes#jcite">370 F.3d 1354</a>, <a href="/s/opinion/0a7288dab8b2e0e9ee9dc2d8937d7419/document/XAPLKN?jcsearch=370%20f%203d%201354&amp;summary=yes#jcite">1367</a> (Fed.Cir.2004). This maxim applies <i>a fortiori<span CLASS="page_no" data-cite="102 uspq 2d 1888" data-cite-type="ReporterOfDecisions" data-cite-pageno="1888" data-primary-citation="102 U.S.P.Q.2d 1881">[**1888]</span> </i>in arts
necessitating laboratory research, clinical studies, and other
trial-and-error experimentation. In the unpredictable arts, rarely if ever
will an untested proposal necessitating further study and optimization meet
the stringent inevitability requirement of inherent anticipation. Although a
patent should not be awarded if a claimed invention is previously described
in a printed publication or patent, or obvious thereover, innovation should
not be impeded by mere speculation.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  On the facts of this case, none of the four cited references describes the
claimed invention or the practice of a method that inherently, necessarily,
carries out the claimed processes. The claims at issue recite a method for
the treatment or prevention of stroke or its recurrence comprising
administering ramipril to a patient diagnosed as in need of such treatment
or prevention. As the majority acknowledges, the references do not expressly
disclose this claimed method. Nor is the claimed method an inherent result
of carrying out what the references describe.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The HOPE paper, the only reference relied on by the majority, describes a
plan designed to administer a combination of ramipril and vitamin E to
patients at risk of a major vascular event including myocardial infarction,
stroke, or death from cardiovascular disease. But HOPE (an acronym for Heart
Outcomes Prevention Evaluation) truly expresses only a hope,
<span CLASS="page_no" data-cite="677 f 3d 1385" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1385" data-primary-citation="677 F.3d 1375">[*1385]</span> 
not achievement of that hope. The HOPE paper itself states that it discloses
only the "design of a . . . trial." J.A. 58. The results of a proposed study
&mdash; involving the administration of two therapeutic agents over four years to
more than 9,000 patients with varied medical histories in 267 hospitals
across nineteen countries &mdash; are neither predictable nor inevitable. J.A. 58,
60, 63. Indeed, the HOPE study provides specific criteria for "early
termination" if the proposed treatment is ineffective. J.A. 65. Inherency
follows from the carrying out of an activity that inherently produces what
is claimed; inherency does not arise from a plan whose description does not
indicate its realization.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The majority states that HOPE discloses a "protocol" for the
administration of ramipril. Majority Op. at 1381. The fact that HOPE is a
planned study, therefore, is not in dispute. The majority's conclusion,
however, rests on its finding that such administration, if carried out,
would inherently treat or prevent stroke. That finding is unsupported <span CLASS="page_no" data-cite="2012 bl 112237 p 9" data-cite-type="Bloomberg" data-cite-pageno="9" data-primary-citation="">[***9]</span> by the
record. As the majority correctly notes, the results of the planned HOPE
study, published in the <i>New England Journal of Medicine</i>years after
Montgomery's priority date and not of record in this case, are "irrelevant
to an anticipation analysis." Majority Op. at 1378. Nevertheless, to the
extent that the majority's reasoning was infected by its consideration of
this non-record evidence, it is worth noting two things. First, the authors
of the <i>New England Journal of Medicine</i>paper acknowledge having subsequently
altered the prior art HOPE study design "to account for the impact of a
possible lag before treatment had its full effect," thus demonstrating that
the prior art HOPE study was, at best, a plan subject to modification.
<i>See</i>The Heart Outcomes Prevention Evaluation Study Investigators, <i>Effects of</i>
<i>an Angiotensin-Converting-Enzyme Inhibitor, Ramipril, on Cardiovascular</i>
<i>Events in High-Risk Patients</i>, 342 New Eng. J. Med. 145, 146 (2000). Second,
that the results of the HOPE study merited publication in the <i>New England</i>
<i>Journal of Medicine</i>, a prestigious and selective peer-reviewed medical
journal of the highest caliber, strongly imply that the study's results were
anything but preordained.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The majority further states that even if HOPE merely proposed
administering ramipril for treatment or prevention of stroke (without
actually doing so), it would still anticipate. Majority Op. at 1381-82. The
majority's view is flawed. A description of a process, even if not carried
out, is an anticipation of that process. But a mere description of a process
that, <i>if it</i>had been carried out, <i>might</i>yield a particular <i>undisclosed</i>result
is not an inherent anticipation of that result. Stated somewhat differently,
inherency requires description of action that inevitably produces a result,
not merely description of action that might have been carried out, but was
not, and might have yielded a particular result, but did not. The HOPE
reference is only a description of what has not been carried out; whether or
not, if carried out, it would inherently accomplish the claimed result is
not before us, for HOPE is only a plan.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  As the majority notes, HOPE does expressly disclose an actual
administration of a low dose of ramipril for a short time period as part of
an initial "randomization" step. But there is no evidence in the record to
prove that HOPE discloses administration sufficient to inevitably treat or
prevent stroke, and the PTO does not argue otherwise. HOPE, therefore,
clearly fails to describe any administration of ramipril at a dose and for a
period of time that would inherently lower the risk of stroke.
<span CLASS="page_no" data-cite="102 uspq 2d 1889" data-cite-type="ReporterOfDecisions" data-cite-pageno="1889" data-primary-citation="102 U.S.P.Q.2d 1881">[**1889]</span> <span CLASS="page_no" data-cite="677 f 3d 1386" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1386" data-primary-citation="677 F.3d 1375">[*1386]</span> 
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Because the majority rests its decision only on HOPE, I will not discuss
the shortcomings of the other references cited by the PTO, but, as indicated
above, in my view they also fail to anticipate the claimed invention, either
expressly or by inherency.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Finally, the majority appears to criticize the disclosure of Montgomery's
application. It must be noted that the only ground of rejection by the
Board, and thus the only ground of rejection <span CLASS="page_no" data-cite="2012 bl 112237 p 10" data-cite-type="Bloomberg" data-cite-pageno="10" data-primary-citation="">[***10]</span> properly before us on appeal,
is anticipation by inherency. Whether Montgomery's pending claims are
patentable on other grounds, such as enablement or obviousness, must be
dealt with by the PTO in the first instance.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  For the foregoing reasons, I respectfully dissent.
</p></div>
<!--BBLS DD 1708231491587-->

</div>
<div class='sideBar printHide clearfix '>
<!-- /Default state -->
<!-- /Display properties -->
<div class='tabsNotepad printHide'>
<div class='tabButtons clearfix'>
<div class='borderTab activeTab' id='buttonTab_general'>
<span>
General Info
</span>
</div>
<div class='borderTab inactiveTab' id='buttonTab_notePad'>
<span>Notepad</span>
</div>
</div>
</div>
<div class='sideBarInner clearfix'>
<div class='sideBarContent bootstrap sidebar ' id='tab_general'>
<div class='sidebarSection'>
<div class='sidebarTitle'>
<span class='left'>BCite Analysis</span>
</div>
<div class='sidebarSubsection sidebarSectionDivider bciteRenderer clearfix'>
<div class='sidebarSubhead bold'>
<a href="/bcite/X1HMT8G003/history">Direct History (2)</a>
</div>
<div class='sidebarItemLabel bold'>
No Negative Direct History
</div>
</div>
<div class='bciteRenderer clearfix sidebarSectionDivider sidebarSubsection'>
<div class='sidebarSubhead bold'>
<a href="/bcite/X1HMT8G003/analysis">Case Analysis (6)</a>
</div>
<div class='bciteResult'>
<img class='icon printOnly' src='/images/citation_icons/positive.png'>
<div class='citation icon positive printHide' title='Positive'></div>
<a class='citationAnalysisLabel' href='/bcite/X1HMT8G003/analysis?analysis=BCITE_POSITIVE_GROUP'>
Positive
</a>
<span class='citationNumberLabel'>
6
</span>
</div>
</div>
<div class='sidebarSubsection clearfix analysisLink'>
<div class='sidebarSubhead small'>
<a href="https://www.bloomberglaw.com/help/BCite_Indicators.htm" class="citatorRenderer">Description of BCite Indicators</a>
</div>
</div>

<div id='generalInfo'>
<div class='sidebarSection'>
<div class='sidebarTitle'>
<span>
General Information
</span>
</div>
<div class='sidebarSubsection sidebarSectionDivider'><div class='facetItemHeading'>Result(s)</div><div class='facetItemLabel'>Order Affirmed</div></div>
<div class='sidebarSubsection sidebarSectionDivider'><div class='facetItemHeading'>Industries</div><div class='facetItemLabel'>Medical Devices</div></div><div class='sidebarSubsection sidebarSectionDivider'><div class='facetItemHeading'>Related Docket(s)</div><div class='facetItemLabel'><a href="/s/opinion/0a7288dab8b2e0e9ee9dc2d8937d7419/document/X1Q6LJKEAN82">11-01376 (Fed. Cir.)</a></div></div><div class='sidebarSubsection sidebarSectionDivider'><div class='facetItemHeading'>Topic(s)</div><div class='facetItemLabel'>Administrative Law</div><div class='facetItemLabel'>Patent Law</div></div>
<div class='sidebarSubsection' id='judges_section'>
<div class='facetItemHeading'>Judge(s)</div>
<div id='judges_section_loader'></div>
</div>
</div>
</div>
</div>
</div>
<div class='sideBarContent clearfix notepad hidden' id='tab_notePad'>
<div id='notepad'>
<div class='notepadInstructions'>
Click anywhere in Notepad to add a note.
</div>
<div class='protoNote note'>
<a class='anchor'></a>
<div class='headerRow'>
<div class='ieFloat'>
<span class='title'></span>
<span class='date'></span>
</div>
<div class='ieFloat right'>
<a class='delete'>
Delete
</a>
<div class='toolDivider'>
|
</div>
<a class='edit'>
Edit
</a>
</div>
<div class='clearfix'></div>
</div>
<div class='body'></div>
<div class='footer'>
<div class='ieFloat'>
<a class='previous'>
Previous
</a>
</div>
<div class='ieFloat pageDisplay'>
<span class='numNoteDisplay'></span>
</div>
<div class='ieFloat right'>
<a class='next'>
Next
</a>
</div>
</div>
</div>
<div class='protoNoteEditor note'>
<div class='headerRow'>
<div class='ieFloat'>
<span class='title'></span>
<span class='date'></span>
</div>
</div>
<div class='body'>
<textarea class='contents'></textarea>
<div class='toolRow'>
<a class='save'>
Save
</a>
<div class='toolDivider'>
|
</div>
<a class='cancel'>
Cancel
</a>
<div class='clearfix'></div>
</div>
</div>
<div class='footer'>
<div class='ieFloat'>
<a class='previous disabled'>
Previous
</a>
</div>
<div class='ieFloat pageDisplay'>
<span class='numNoteDisplay disabled'></span>
</div>
<div class='ieFloat right'>
<a class='next disabled'>
Next
</a>
</div>
</div>
</div>
<div class='protoConfirmDelete'>
<div class='popupWindowOuter'>
<div class='popupWindowInner'>
<div class='clearfix popupTitle'>
<div class='close' onclick='closePopup()'></div>
<h2>
Delete Note
</h2>
</div>
<div class='popupContent'>
<div class='sectionLabel'>
Are you sure you want to delete this note?
<br>
<br>
<br>
<br>
</div>
</div>
<div class='popUpActions'>
<button class='bootstrap skinButton popup action right'>
<span>
Delete
</span>
</button>
<button class='bootstrap skinButton popup cancel right' onclick='closePopup()'>
<span>
Cancel
</span>
</button>
</div>
</div>
</div>
</div>
</div>

</div>
</div>

</div>
<div class='clearfix'></div>
</div>

<div class='keywordSearch' id='keyword_search'>
<a href="javascript:Blaw__findPrevKeyWord();redrawPrevNextButtons();" id="keyword_search_previous">Previous Keyword</a>
|
<a href="javascript:Blaw__findNextKeyWord();redrawPrevNextButtons();" id="keyword_search_next">Next Keyword</a>
</div>
<div class='pageLoader'></div>
<div class='browserPopupContainer' id='browserPopup'>
<div class='browserTitle'>
<div class='close' onclick='$("#browserPopup").bbTocBrowser(false);'></div>
<h2 class='popup_title'></h2>
</div>
<div class='browserPopupContent popup_content' id='browserPopupContent'></div>
</div>
<div class='maskOverlay' id='ajax_browser_mask'></div>


<div class='clearfix'></div>
</div>
</div>
<!-- _enter_client_matter.haml begin -->
<div class='clientMatterContainer hidden' id='clientMatterContainer'>
<form accept-charset="UTF-8" action="/client_matter/session/create" id="startClientMatterSessionForm" method="post"><div style="margin:0;padding:0;display:inline"><input name="utf8" type="hidden" value="&#x2713;" /><input name="authenticity_token" type="hidden" value="NiJ+70/qv61N1TFnbttr4ZzRa7IGhB5DMvou0CKGUXA=" /></div>
<input id="create_client_matter" name="create_client_matter" type="hidden" value="false" />
<div class='clearfix popupTitle'>
<div class='close' onclick='cancelClientMatterPopup()'></div>
<h2>
Enter a Client Matter
</h2>
</div>
<div class='popUpContent'>
<div class='clientMatterPopupHeader'>
Your firm optionally allows a client matter to be selected while you are using Bloomberg Law.
Please select from a recently used Client Matter or enter a Client Matter manually.
</div>
<div class='error' id='clientMatterLabelErrors' style='display:none'></div>
<div class='error' id='attorneyNumberLabelErrors' style='display:none'></div>
<div class='row sources clearfix'>
<div class='labelHolder'>
<span class='label'>Client Matter</span>
</div>
<div class='inputContainer'>
<input autocomplete="off" class="autocompleteTextField input_auto autocompleteForm" data-context="CLIENT_MATTERS" data-highlight-term="true" data-select-callback="applyClientMatterFromAutocompleteSelection" data-show-no-matches="false" data-url="/autocomplete/lookup" id="client_matter_label" name="client_matter_label" type="text" value="" />
<script type="text/javascript">
//<![CDATA[
jQuery().ready(function ($) { $('#client_matter_label').bbAutocomplete(); });
//]]>
</script>
</div>
</div>
<div class='row clientMatterSuppressionCheckholder' id='clientMatterSuppressionCheckholder'>
<label>
<input id="suppress_client_matter_prompt_enabled" name="suppress_client_matter_prompt_enabled" type="hidden" value="1" />
<input checked="checked" id="suppress_client_matter_prompt" name="suppress_client_matter_prompt" type="checkbox" value="1" />
<label for="suppress_client_matter_prompt">Do not remind me again this session</label>
</label>
</div>
<div class='clientMatterText'>
Please contact your administrator if you have questions about client matter.
</div>
</div>
<div class='popUpActions'>
<button class='bootstrap skinButton popup right' type='submit'>
<span>
Submit
</span>
</button>
<button class='bootstrap skinButton popup cancel right' onclick='cancelClientMatterPopup();' type='button'>
<span>
Cancel
</span>
</button>
</div>
</form>

<div id='createClientMatterForm' style='display:none'>
<div class='clearfix popupTitle'>
<h2>
Unrecognized Client Matter
</h2>
</div>
<div class='div'>
Client Matter
<span id='new_client_matter_label'>&nbsp;</span>
does not currently exist in Bloomberg Law. Would you like to add this client matter to the system?
</div>
<div class='popUpActions'>
<button class='bootstrap skinButton popup action right' type='button'>
<span>
Yes
</span>
</button>
<button class='bootstrap skinButton popup cancel right' type='button'>
<span>
No
</span>
</button>
</div>
</div>
</div>
<!-- _enter_client_matter.haml begin -->

<div id='loading_container'></div>
<div class='fixedControls menuHolder printHide' id='bottom_menu_row'>
<div class='menuButton' id='pde_tray_menu'>
<div class='queueImageHolder'></div>
<div class='indicator num_of_pde_tray_items'></div>
</div>
<div class='clearfix'></div>
</div>
<div class='menuItem bottomMenu' id='pde_tray'>
<div class='inner'>
<div class='heading'>
<div class='title'>
Queue
<span class='indicator num_of_pde_tray_items'></span>
<!-- =pde_tray_count_from_session -->
</div>
<div class='bootstrap closeIcon right' id='pde_tray_close_button'></div>
<div class='clearfix'></div>
</div>
<div class='actions hasItems' id='pde_tray_has_items'>
<div class='selection'>
<div class='trayCheckHolder'>
<input id='pde_tray_select_all' type='checkbox'>
</div>
Select All
</div>
<div class='tools'>
<a onclick='javascript:PDETray_default.downloadSelection();'>
Print/Download
</a>
|
<a onclick='javascript:PDETray_default.emailSelection();'>
Email
</a>
|
<a onclick='javascript:PDETray_default.workspaceSelection();'>
+ Workspace
</a>
|
<a onclick='javascript:PDETray_default.deleteSelection();'>
Delete
</a>
</div>
<div class='clearfix'></div>
</div>
<div class='actions noItems' id='pde_tray_no_items'>
<div class='title'>
You have no items in your Queue
</div>
<div class='clearfix'></div>
</div>
<div class='itemsHolder' id='pde_tray_items'></div>
</div>
</div>

<div class='maskOverlay' id='pde_tray_mask'></div>

<script language='javascript'>
var SHOW_AUDIT = false;
var ROOT_PATH = "/";
var RAILS_ROOT = "/";
var CONTEXT_PATH = "/";
var DOC_ROOT_PATH = "/s/opinion/0a7288dab8b2e0e9ee9dc2d8937d7419/";
var RESULTS_ROOT_PATH = "/search/results/";
var SELECTED_CONTEXT = "";
var MODULE_PATH;
MODULE_PATH = "/document";
var CRUMB_ID = "0a7288dab8b2e0e9ee9dc2d8937d7419";
var BILLING_CONFIGURATION = {"DOCKET":true,"NEWS":false,"LAW":true,"ADVANCED_LEGAL":true,"PATENT":true,"PATENT_ASSIGNMENT":true,"PEOPLE":false,"OPINION":true,"CITATION":false,"BREAKING":true,"DOCKET_REQUESTS":true,"COMPANY_FILINGS_EDGAR":false,"COMPANY_FILINGS_DOCKETS":false,"COMPANY_FILINGS_OTHER":false,"CORP_ACTIONS":true,"ECO_SEARCH":true,"EDGAR_SEARCH":true,"EXAMPLE_DOCUMENTS":true,"CLAUSE_SEARCH":true,"LEG":true,"REG":true,"BOOLEAN":false,"SIMPLE":false,"COMPANY_DOCKETS":true,"TOC_SEARCH":true,"IMMUTABLE_LAW_SEARCH":true};
var CONTEXT_BILLING_POLICY_KEY = "";
var ELITE_ENABLED = false;
var CLIENT_MATTER_PROMPT_ENABLED = false;
var CLIENT_MATTER_ON_LOGIN_ENABLED = false;
var SUPPRESS_CLIENT_MATTER_PROMPT = false;
var clientMatterActive = false;
var currentClientMatter = '';
var currentAttorneyNumber = '';
var clientMatterHaltedForm = null;
var USER_ID = 'un=373038066';
var SESSION_ID = '63166_a5929cc15e1bfd637ed52768bec5d196';
var NTPT_REDIRECTED_EVENT = '';
var NTPT_PGEXTRA = '&activityType=ENTITY&subActivityType=DOCUMENT_VIEWED&pageId=&activityInstanceId=ENTITY043a69&previousPageId=&previousActivityInstanceId=ENTITY77b272&previousActivityType=ENTITY&previousSubActivityType=DOCUMENT_VIEWED&previousActivityTime=2014-02-02T00:45:56-05:00';
var NTPT_GLBLEXTRA = 'un=373038066&sessionId=63166_a5929cc15e1bfd637ed52768bec5d196&auth=true';
var BROWSER_COMPATIBILITY_WARNING = 'false';
var SHOW_MODAL = false;
var JUG;
$(document).ready(function(){
setTimeout(framework_getPageState,500);
framework_bindGlobalResizeElements();
notepad_onDocumentLoaded();
<!-- /DRQS 24932463 -->
$("#downloadPopupLinkForm a").removeAttr("href");
$('#startClientMatterSessionForm').submit(function() {
  createClientMatterSessionFromForm(this);
  return false;
});

var t = $('.clientMattersTableEl');

jQuery.each(t, function(name, value) {
  try {
    var this_value =  $.trim(String(value.innerHTML));
    var this_final_value = this_value.length > 22 ? this_value.substring(0,9)+"..." : this_value;
    value.innerHTML = this_final_value;
  } catch (e) {}
});

$('#startClientMatterSessionForm .recentlyUsed td').click(function() {
  $('#client_matter_label').val($.trim($(this).attr("title")));
});

});
</script>
<script type='text/javascript'>
DOCUMENT_SHOW_SIDEBAR="true";
DOCUMENT_HAS_SIDEBAR_INFO="true";
DOCUMENT_IS_IFRAME="";
NTPT_PGEXTRA = 'documentSearchType=OPINION&docId=X1HMT8G003&docType=OPINIONS&contentClass=LEGAL&activityType=ENTITY&subActivityType=DOCUMENT_VIEWED&pageId=&activityInstanceId=ENTITY77b272&previousPageId=&previousActivityInstanceId=ENTITYb30a05&previousActivityType=ENTITY&previousSubActivityType=DOCUMENT_VIEWED&previousActivityTime=2014-02-02T00:45:53-05:00';
FLUID_LAYOUT="false";
FULL_DOC_ID = 'X1HMT8G003';
NOTEPAD_UUID="11082191";
NOTEPAD_DOC_ID="X1HMT8G003";
$('#page_loader').show().spin();
JUDGE_IDS=["1718421","3408847","4063892"];
JUDGE_NAMES=null;
</script>

<script src="/javascripts/activity_tracking/ni.js?1376494218" type="text/javascript"></script>
<script src="/javascripts/activity_tracking/tracking.js?1384975732" type="text/javascript"></script>
<div class='footer'>
<div class='footerContent printHide'>
<div class='logoContainer grid eight'>
<div class='copyright'>
&copy; 2014 The Bureau of National Affairs, Inc. All Rights Reserved.
 | 
<a href="#" class="menuLink" onclick="open_tos_or_privacy('X3BPR08'); return false;">Terms of Service</a>
 | 
<a href="#" class="menuLink" onclick="open_tos_or_privacy('X3BPH08'); return false;">Privacy Policy</a>
</div>
<a class='logo' href='/home'></a>
<div class='version'>
2.
231154
Gem
0.176.7
231497
 - 3.0.20
</div>
<div class='helpContainer'>
<div class='helpDesk'></div>
<a href="/help/BLAWHelpSystem.htm#Contact_Us.htm" class="menuLink">Submit Feedback</a>
 | 
<a href="mailto:blawhelp@bna.com" class="menuLink">blawhelp@bna.com</a>
</div>
</div>
</div>

</div>
</div>
</body>
</html>
